[
    {
        "text": "and I will rather than my give an",
        "start": 0.0,
        "duration": 6.899
    },
    {
        "text": "introduction of their backgrounds I have",
        "start": 2.1,
        "duration": 6.87
    },
    {
        "text": "asked them to please give a little",
        "start": 6.899,
        "duration": 3.87
    },
    {
        "text": "background on how they got from their",
        "start": 8.97,
        "duration": 3.749
    },
    {
        "text": "advanced degree to where they are a",
        "start": 10.769,
        "duration": 12.59
    },
    {
        "text": "chanson thank you thank you so thank you",
        "start": 12.719,
        "duration": 12.991
    },
    {
        "text": "it's a pleasure to be here today it's",
        "start": 23.359,
        "duration": 4.84
    },
    {
        "text": "been a while since I was in Ann Arbor so",
        "start": 25.71,
        "duration": 6.21
    },
    {
        "text": "it's nice to come back so I'm gonna give",
        "start": 28.199,
        "duration": 5.641
    },
    {
        "text": "you an overview of the economy on",
        "start": 31.92,
        "duration": 5.069
    },
    {
        "text": "ecology program as a whole and then Mike",
        "start": 33.84,
        "duration": 4.41
    },
    {
        "text": "is going to spend most of the time",
        "start": 36.989,
        "duration": 4.59
    },
    {
        "text": "talking about how we use aspects of",
        "start": 38.25,
        "duration": 4.8
    },
    {
        "text": "bioinformatics and computational biology",
        "start": 41.579,
        "duration": 6.181
    },
    {
        "text": "and developing novel oncology drugs as",
        "start": 43.05,
        "duration": 6.12
    },
    {
        "text": "part of the background as - we do teach",
        "start": 47.76,
        "duration": 4.439
    },
    {
        "text": "myself I was I got my PhD in the",
        "start": 49.17,
        "duration": 6.0
    },
    {
        "text": "University of London I came over to the",
        "start": 52.199,
        "duration": 5.52
    },
    {
        "text": "US and did postdocs at Memorial",
        "start": 55.17,
        "duration": 4.47
    },
    {
        "text": "sloan-kettering and cancer biology and",
        "start": 57.719,
        "duration": 4.921
    },
    {
        "text": "then moved to MIT and the Whitehead",
        "start": 59.64,
        "duration": 4.739
    },
    {
        "text": "genome Center for many years it's been a",
        "start": 62.64,
        "duration": 4.71
    },
    {
        "text": "lot of time in the genome Center with",
        "start": 64.379,
        "duration": 6.151
    },
    {
        "text": "Eric Lander and working on genome",
        "start": 67.35,
        "duration": 6.42
    },
    {
        "text": "project from there I went to work for an",
        "start": 70.53,
        "duration": 5.46
    },
    {
        "text": "X Michigan alum Francis Collins at the",
        "start": 73.77,
        "duration": 4.65
    },
    {
        "text": "National Institutes of Health work for",
        "start": 75.99,
        "duration": 4.86
    },
    {
        "text": "practice for a few years in the early",
        "start": 78.42,
        "duration": 5.28
    },
    {
        "text": "days of the genome Center and then moved",
        "start": 80.85,
        "duration": 7.949
    },
    {
        "text": "into industry biotech and pharma so it's",
        "start": 83.7,
        "duration": 6.84
    },
    {
        "text": "a while ago since I was sitting in UFC",
        "start": 88.799,
        "duration": 4.351
    },
    {
        "text": "but you know the you know all of us you",
        "start": 90.54,
        "duration": 4.619
    },
    {
        "text": "know in the company today of have",
        "start": 93.15,
        "duration": 4.25
    },
    {
        "text": "academic backgrounds that led us into",
        "start": 95.159,
        "duration": 4.561
    },
    {
        "text": "you know basically pharmaceutical and",
        "start": 97.4,
        "duration": 3.91
    },
    {
        "text": "drug development research and so I think",
        "start": 99.72,
        "duration": 2.88
    },
    {
        "text": "one of the things we're here today is to",
        "start": 101.31,
        "duration": 2.94
    },
    {
        "text": "show you exactly not quite such a big",
        "start": 102.6,
        "duration": 4.379
    },
    {
        "text": "step big change from from academic",
        "start": 104.25,
        "duration": 6.45
    },
    {
        "text": "research into what we do so let me go",
        "start": 106.979,
        "duration": 7.14
    },
    {
        "text": "into a big background so Janssen",
        "start": 110.7,
        "duration": 5.97
    },
    {
        "text": "pharmaceuticals see the logo on the",
        "start": 114.119,
        "duration": 7.231
    },
    {
        "text": "bottom is part of Johnson & Johnson so",
        "start": 116.67,
        "duration": 6.57
    },
    {
        "text": "Johnson and Johnson you know like baby",
        "start": 121.35,
        "duration": 3.869
    },
    {
        "text": "powder will let other stuff we need I",
        "start": 123.24,
        "duration": 4.68
    },
    {
        "text": "never actually see any of that Janssen",
        "start": 125.219,
        "duration": 5.79
    },
    {
        "text": "is the pharmaceutical arm of Johnson and",
        "start": 127.92,
        "duration": 5.01
    },
    {
        "text": "it has multiple therapeutic areas",
        "start": 131.009,
        "duration": 2.911
    },
    {
        "text": "cardiovascular",
        "start": 132.93,
        "duration": 6.32
    },
    {
        "text": "you know the oncology neurosciences",
        "start": 133.92,
        "duration": 8.7
    },
    {
        "text": "virology as well as different disease",
        "start": 139.25,
        "duration": 5.53
    },
    {
        "text": "areas and so we can focus today on",
        "start": 142.62,
        "duration": 4.4
    },
    {
        "text": "oncology which is the single largest",
        "start": 144.78,
        "duration": 5.67
    },
    {
        "text": "research area within the pharmaceutical",
        "start": 147.02,
        "duration": 7.15
    },
    {
        "text": "business it's a global company",
        "start": 150.45,
        "duration": 5.4
    },
    {
        "text": "we've scattered you know in the US",
        "start": 154.17,
        "duration": 5.76
    },
    {
        "text": "Europe Asia you know basically and and a",
        "start": 155.85,
        "duration": 8.24
    },
    {
        "text": "lot of pharmaceutical products globally",
        "start": 159.93,
        "duration": 8.639
    },
    {
        "text": "so we've had a big growth over the last",
        "start": 164.09,
        "duration": 6.76
    },
    {
        "text": "few years this is a little bit of sort",
        "start": 168.569,
        "duration": 5.661
    },
    {
        "text": "of corporate advertising it is gone but",
        "start": 170.85,
        "duration": 6.54
    },
    {
        "text": "we you know on cut you know we've been",
        "start": 174.23,
        "duration": 6.039
    },
    {
        "text": "had a run of good luck or success if you",
        "start": 177.39,
        "duration": 4.319
    },
    {
        "text": "want to put it that way over the last",
        "start": 180.269,
        "duration": 3.511
    },
    {
        "text": "few years and launched it a large number",
        "start": 181.709,
        "duration": 4.891
    },
    {
        "text": "of drug our portfolio is really totally",
        "start": 183.78,
        "duration": 5.91
    },
    {
        "text": "you know revitalized now you know with",
        "start": 186.6,
        "duration": 4.949
    },
    {
        "text": "this and over the last few years you",
        "start": 189.69,
        "duration": 3.24
    },
    {
        "text": "know we have been one of the more",
        "start": 191.549,
        "duration": 3.151
    },
    {
        "text": "productive companies and we can go show",
        "start": 192.93,
        "duration": 6.21
    },
    {
        "text": "you in essence around the oncology",
        "start": 194.7,
        "duration": 7.02
    },
    {
        "text": "program in more details of that as we go",
        "start": 199.14,
        "duration": 7.17
    },
    {
        "text": "forward but our oncology vision is a",
        "start": 201.72,
        "duration": 7.47
    },
    {
        "text": "bold one so what we won't we what we're",
        "start": 206.31,
        "duration": 6.6
    },
    {
        "text": "trying to do is to change the way cancer",
        "start": 209.19,
        "duration": 4.859
    },
    {
        "text": "drugs are developed",
        "start": 212.91,
        "duration": 2.82
    },
    {
        "text": "traditionally cancer drugs are being",
        "start": 214.049,
        "duration": 3.331
    },
    {
        "text": "developed in patients with late stage",
        "start": 215.73,
        "duration": 5.72
    },
    {
        "text": "metastatic disease often you know by",
        "start": 217.38,
        "duration": 7.02
    },
    {
        "text": "inhibiting signal transduction pathways",
        "start": 221.45,
        "duration": 5.02
    },
    {
        "text": "with small molecules the block signaling",
        "start": 224.4,
        "duration": 4.23
    },
    {
        "text": "from the cell that helped with you know",
        "start": 226.47,
        "duration": 5.16
    },
    {
        "text": "cell to divide and proliferate and then",
        "start": 228.63,
        "duration": 4.8
    },
    {
        "text": "a little with somatic genomic",
        "start": 231.63,
        "duration": 3.87
    },
    {
        "text": "alterations leading to the generation of",
        "start": 233.43,
        "duration": 4.589
    },
    {
        "text": "sort of the hallmark answer where the",
        "start": 235.5,
        "duration": 4.56
    },
    {
        "text": "cell is able to evade the immune system",
        "start": 238.019,
        "duration": 4.771
    },
    {
        "text": "its ability to repair DNA it's inhibited",
        "start": 240.06,
        "duration": 6.36
    },
    {
        "text": "its ability to go into a ptosis block is",
        "start": 242.79,
        "duration": 6.569
    },
    {
        "text": "to think about basically trying to move",
        "start": 246.42,
        "duration": 7.23
    },
    {
        "text": "the the therapeutic process much earlier",
        "start": 249.359,
        "duration": 6.451
    },
    {
        "text": "into the process but for patients of",
        "start": 253.65,
        "duration": 3.54
    },
    {
        "text": "development develop metastatic",
        "start": 255.81,
        "duration": 4.799
    },
    {
        "text": "disseminated disease and to do this by",
        "start": 257.19,
        "duration": 5.099
    },
    {
        "text": "combination of therapeutics and",
        "start": 260.609,
        "duration": 3.841
    },
    {
        "text": "diagnostics where we can find patients",
        "start": 262.289,
        "duration": 4.581
    },
    {
        "text": "at high risk and intervene earlier",
        "start": 264.45,
        "duration": 4.31
    },
    {
        "text": "and we hope by intervening earlier",
        "start": 266.87,
        "duration": 3.57
    },
    {
        "text": "you'll have team of cells it will be",
        "start": 268.76,
        "duration": 3.45
    },
    {
        "text": "less prone to the development of drug",
        "start": 270.44,
        "duration": 3.72
    },
    {
        "text": "resistance because the major problem we",
        "start": 272.21,
        "duration": 4.41
    },
    {
        "text": "fail we face in oncology development",
        "start": 274.16,
        "duration": 6.12
    },
    {
        "text": "today is that a new compound will you",
        "start": 276.62,
        "duration": 6.09
    },
    {
        "text": "know I give you one example say the be",
        "start": 280.28,
        "duration": 6.389
    },
    {
        "text": "RAF inhibitor that inhibits signaling",
        "start": 282.71,
        "duration": 7.53
    },
    {
        "text": "through the be RAF gene if you look at",
        "start": 286.669,
        "duration": 5.931
    },
    {
        "text": "you know basically images of patients",
        "start": 290.24,
        "duration": 5.04
    },
    {
        "text": "with late stage melanoma you'll see",
        "start": 292.6,
        "duration": 4.569
    },
    {
        "text": "systemic disease throughout the",
        "start": 295.28,
        "duration": 4.65
    },
    {
        "text": "patient's body you give them and if",
        "start": 297.169,
        "duration": 5.121
    },
    {
        "text": "these patients have an active the RAF",
        "start": 299.93,
        "duration": 5.07
    },
    {
        "text": "gene and the drive their disease you",
        "start": 302.29,
        "duration": 5.349
    },
    {
        "text": "give them a b-raf inhibitor within a",
        "start": 305.0,
        "duration": 5.1
    },
    {
        "text": "matter of weeks that systemic disease",
        "start": 307.639,
        "duration": 4.731
    },
    {
        "text": "clears up and become invisible",
        "start": 310.1,
        "duration": 4.2
    },
    {
        "text": "radiologically you know the patient",
        "start": 312.37,
        "duration": 3.549
    },
    {
        "text": "looks like they didn't completely cured",
        "start": 314.3,
        "duration": 4.44
    },
    {
        "text": "the problem is is there is a residual",
        "start": 315.919,
        "duration": 5.191
    },
    {
        "text": "disease that will gradually emerge over",
        "start": 318.74,
        "duration": 4.92
    },
    {
        "text": "a period of time and that nine months to",
        "start": 321.11,
        "duration": 4.38
    },
    {
        "text": "a year later the patient exactly they",
        "start": 323.66,
        "duration": 3.36
    },
    {
        "text": "were now except with fully drug",
        "start": 325.49,
        "duration": 4.23
    },
    {
        "text": "resistant disease so we have an ability",
        "start": 327.02,
        "duration": 4.47
    },
    {
        "text": "to kill off the majority of the team",
        "start": 329.72,
        "duration": 3.54
    },
    {
        "text": "itself through therapeutic intervention",
        "start": 331.49,
        "duration": 3.75
    },
    {
        "text": "but we are unable to kill all of the",
        "start": 333.26,
        "duration": 4.71
    },
    {
        "text": "cells over period of time resistance and",
        "start": 335.24,
        "duration": 4.739
    },
    {
        "text": "merges either through mechanisms where",
        "start": 337.97,
        "duration": 3.48
    },
    {
        "text": "the drug will no longer bind to the",
        "start": 339.979,
        "duration": 3.631
    },
    {
        "text": "target or the cells will activate",
        "start": 341.45,
        "duration": 4.92
    },
    {
        "text": "alternative paths apart ways to evade",
        "start": 343.61,
        "duration": 4.86
    },
    {
        "text": "blockade a particular proliferation",
        "start": 346.37,
        "duration": 4.799
    },
    {
        "text": "pathway to get around that blockade but",
        "start": 348.47,
        "duration": 4.14
    },
    {
        "text": "either way the cell develops resistance",
        "start": 351.169,
        "duration": 4.831
    },
    {
        "text": "to therapy and so most of our patients",
        "start": 352.61,
        "duration": 5.49
    },
    {
        "text": "still die of cauca resistant disease we",
        "start": 356.0,
        "duration": 4.08
    },
    {
        "text": "may provide you know it's a survival",
        "start": 358.1,
        "duration": 3.6
    },
    {
        "text": "benefit the patient may live for longer",
        "start": 360.08,
        "duration": 3.42
    },
    {
        "text": "period of time but we're not curing",
        "start": 361.7,
        "duration": 5.21
    },
    {
        "text": "patient with getting into that cancer",
        "start": 363.5,
        "duration": 5.33
    },
    {
        "text": "so at the end of the day we hesitate to",
        "start": 366.91,
        "duration": 4.02
    },
    {
        "text": "use the word cure because it is such an",
        "start": 368.83,
        "duration": 3.57
    },
    {
        "text": "ambitious goal at the end of the day",
        "start": 370.93,
        "duration": 3.36
    },
    {
        "text": "what we're trying to do is to basically",
        "start": 372.4,
        "duration": 4.86
    },
    {
        "text": "make oncology drugs that be much more",
        "start": 374.29,
        "duration": 4.89
    },
    {
        "text": "than provide a few months of survival",
        "start": 377.26,
        "duration": 4.11
    },
    {
        "text": "benefit cancer patients but eventually",
        "start": 379.18,
        "duration": 4.65
    },
    {
        "text": "hopefully lead to a cure of some cancers",
        "start": 381.37,
        "duration": 5.28
    },
    {
        "text": "and eventually audiences I'll skip over",
        "start": 383.83,
        "duration": 5.7
    },
    {
        "text": "this is a relatively large group it is",
        "start": 386.65,
        "duration": 5.76
    },
    {
        "text": "going so you know within the oncology",
        "start": 389.53,
        "duration": 6.09
    },
    {
        "text": "orgonite organization we are we are",
        "start": 392.41,
        "duration": 5.25
    },
    {
        "text": "integrated in a way that from research",
        "start": 395.62,
        "duration": 3.69
    },
    {
        "text": "and development all the way through to",
        "start": 397.66,
        "duration": 3.39
    },
    {
        "text": "commercialization and an integrated",
        "start": 399.31,
        "duration": 3.81
    },
    {
        "text": "group so this is this is different from",
        "start": 401.05,
        "duration": 4.5
    },
    {
        "text": "many many other climate companies do",
        "start": 403.12,
        "duration": 4.05
    },
    {
        "text": "base of the organization selves",
        "start": 405.55,
        "duration": 3.45
    },
    {
        "text": "horizontally we have an integrated team",
        "start": 407.17,
        "duration": 3.54
    },
    {
        "text": "intelligent research and development",
        "start": 409.0,
        "duration": 3.9
    },
    {
        "text": "from Target discovery to target",
        "start": 410.71,
        "duration": 4.23
    },
    {
        "text": "validation development of small molecule",
        "start": 412.9,
        "duration": 4.41
    },
    {
        "text": "a lot of quality inhibitors into",
        "start": 414.94,
        "duration": 4.32
    },
    {
        "text": "clinical testing and so on and through",
        "start": 417.31,
        "duration": 4.68
    },
    {
        "text": "regulatory approval all this is done as",
        "start": 419.26,
        "duration": 5.61
    },
    {
        "text": "an integrated and an team you know",
        "start": 421.99,
        "duration": 5.34
    },
    {
        "text": "typically you know crumb it takes about",
        "start": 424.87,
        "duration": 6.42
    },
    {
        "text": "you know recently you know the fastest",
        "start": 427.33,
        "duration": 5.82
    },
    {
        "text": "drugs being approved take about three",
        "start": 431.29,
        "duration": 3.6
    },
    {
        "text": "years from the time a drug is first",
        "start": 433.15,
        "duration": 4.26
    },
    {
        "text": "tested in humans in the clinic pull the",
        "start": 434.89,
        "duration": 4.86
    },
    {
        "text": "way through to approval some of the",
        "start": 437.41,
        "duration": 3.48
    },
    {
        "text": "recent drugs have been done in about",
        "start": 439.75,
        "duration": 3.09
    },
    {
        "text": "three years typically the process is a",
        "start": 440.89,
        "duration": 3.84
    },
    {
        "text": "lot longer five to eight years but we",
        "start": 442.84,
        "duration": 6.27
    },
    {
        "text": "targeted therapy being quicker the you",
        "start": 444.73,
        "duration": 6.54
    },
    {
        "text": "know and then we also want to be able to",
        "start": 449.11,
        "duration": 4.59
    },
    {
        "text": "take these compounds out develop",
        "start": 451.27,
        "duration": 4.17
    },
    {
        "text": "combination therapy to integrate them",
        "start": 453.7,
        "duration": 4.469
    },
    {
        "text": "into existing regimes of therapy in ways",
        "start": 455.44,
        "duration": 7.44
    },
    {
        "text": "that we can affect Asians you know most",
        "start": 458.169,
        "duration": 7.981
    },
    {
        "text": "effectively our goal for awhile was to",
        "start": 462.88,
        "duration": 4.98
    },
    {
        "text": "be one of the top five oncology",
        "start": 466.15,
        "duration": 5.22
    },
    {
        "text": "companies in by 2015 this is actually we",
        "start": 467.86,
        "duration": 7.35
    },
    {
        "text": "you know we gangjae began its investment",
        "start": 471.37,
        "duration": 6.9
    },
    {
        "text": "in alcohol tea in 2008 at that time was",
        "start": 475.21,
        "duration": 5.43
    },
    {
        "text": "a very minor player in oncology and",
        "start": 478.27,
        "duration": 3.72
    },
    {
        "text": "we've had a significant growth over",
        "start": 480.64,
        "duration": 3.029
    },
    {
        "text": "those last few years so now with the",
        "start": 481.99,
        "duration": 6.62
    },
    {
        "text": "fourth largest company in oncology today",
        "start": 483.669,
        "duration": 7.651
    },
    {
        "text": "right right here only only Celgene the",
        "start": 488.61,
        "duration": 4.63
    },
    {
        "text": "violence and Roshan a bigger than we are",
        "start": 491.32,
        "duration": 4.89
    },
    {
        "text": "so we're now in large a large oncology",
        "start": 493.24,
        "duration": 4.739
    },
    {
        "text": "company with a lot of diverse you know",
        "start": 496.21,
        "duration": 3.25
    },
    {
        "text": "opportunities",
        "start": 497.979,
        "duration": 2.861
    },
    {
        "text": "one of the really attractive things",
        "start": 499.46,
        "duration": 3.21
    },
    {
        "text": "about becoming bigger I'm not successful",
        "start": 500.84,
        "duration": 3.75
    },
    {
        "text": "with the quality of drugs we get to work",
        "start": 502.67,
        "duration": 3.9
    },
    {
        "text": "on it much better you know we can now",
        "start": 504.59,
        "duration": 4.5
    },
    {
        "text": "compete the license really acted",
        "start": 506.57,
        "duration": 4.47
    },
    {
        "text": "exciting compounds we have bigger",
        "start": 509.09,
        "duration": 4.2
    },
    {
        "text": "internal teams able to develop compounds",
        "start": 511.04,
        "duration": 4.2
    },
    {
        "text": "that are much more essentially much more",
        "start": 513.29,
        "duration": 3.72
    },
    {
        "text": "interesting much more active in patience",
        "start": 515.24,
        "duration": 3.93
    },
    {
        "text": "and so certainly one of the advantages",
        "start": 517.01,
        "duration": 4.29
    },
    {
        "text": "of growth that you can date it can work",
        "start": 519.17,
        "duration": 3.27
    },
    {
        "text": "with much more exciting and interesting",
        "start": 521.3,
        "duration": 5.57
    },
    {
        "text": "compounds as you develop that capability",
        "start": 522.44,
        "duration": 8.25
    },
    {
        "text": "are we based across the globe but the",
        "start": 526.87,
        "duration": 4.99
    },
    {
        "text": "main sights here",
        "start": 530.69,
        "duration": 2.88
    },
    {
        "text": "Mike and I are based here in Spring",
        "start": 531.86,
        "duration": 3.45
    },
    {
        "text": "House in Pennsylvania this is just north",
        "start": 533.57,
        "duration": 6.39
    },
    {
        "text": "of Philadelphia we also have clinical",
        "start": 535.31,
        "duration": 6.06
    },
    {
        "text": "development in Raritan in New Jersey",
        "start": 539.96,
        "duration": 4.95
    },
    {
        "text": "just to the north of site there and then",
        "start": 541.37,
        "duration": 5.76
    },
    {
        "text": "other major risa excited in Belgium and",
        "start": 544.91,
        "duration": 5.61
    },
    {
        "text": "dear sir a town me in Brussels and",
        "start": 547.13,
        "duration": 5.91
    },
    {
        "text": "Antwerp in Belgium so our major research",
        "start": 550.52,
        "duration": 4.44
    },
    {
        "text": "sites are here in Belgium and in each go",
        "start": 553.04,
        "duration": 4.35
    },
    {
        "text": "to the US and then we have you know",
        "start": 554.96,
        "duration": 4.32
    },
    {
        "text": "affiliated clinical sites globally",
        "start": 557.39,
        "duration": 3.39
    },
    {
        "text": "you know Chang in China and Shanghai",
        "start": 559.28,
        "duration": 5.13
    },
    {
        "text": "Tokyo also Beijing other sites in Europe",
        "start": 560.78,
        "duration": 7.62
    },
    {
        "text": "and the US for you know clinical so but",
        "start": 564.41,
        "duration": 5.25
    },
    {
        "text": "basically from a research and",
        "start": 568.4,
        "duration": 3.3
    },
    {
        "text": "development perspective you know we're",
        "start": 569.66,
        "duration": 3.81
    },
    {
        "text": "focused on the east coast of the US and",
        "start": 571.7,
        "duration": 4.28
    },
    {
        "text": "indulgent",
        "start": 573.47,
        "duration": 2.51
    },
    {
        "text": "so one of the things that Mike will talk",
        "start": 576.74,
        "duration": 4.12
    },
    {
        "text": "about in details around some of the",
        "start": 579.3,
        "duration": 3.21
    },
    {
        "text": "computational biology programs we'll be",
        "start": 580.86,
        "duration": 4.17
    },
    {
        "text": "using is rather than attempting to",
        "start": 582.51,
        "duration": 4.83
    },
    {
        "text": "address all of cancer so if you think of",
        "start": 585.03,
        "duration": 5.22
    },
    {
        "text": "you know the the oncologist here people",
        "start": 587.34,
        "duration": 4.71
    },
    {
        "text": "you know oncology is somewhere around",
        "start": 590.25,
        "duration": 5.04
    },
    {
        "text": "200 different diseases and not just a",
        "start": 592.05,
        "duration": 6.23
    },
    {
        "text": "single disease but if you look at the",
        "start": 595.29,
        "duration": 5.55
    },
    {
        "text": "pista chemical subtyping of the disease",
        "start": 598.28,
        "duration": 4.62
    },
    {
        "text": "you can identify about 200 different",
        "start": 600.84,
        "duration": 4.23
    },
    {
        "text": "cancers all the way to driven by",
        "start": 602.9,
        "duration": 3.7
    },
    {
        "text": "different subsets different somatic",
        "start": 605.07,
        "duration": 3.15
    },
    {
        "text": "changes different molecular changes",
        "start": 606.6,
        "duration": 3.72
    },
    {
        "text": "different immune responses and so on and",
        "start": 608.22,
        "duration": 4.74
    },
    {
        "text": "so on the cancer is about 200 different",
        "start": 610.32,
        "duration": 6.87
    },
    {
        "text": "diseases we've tried to focus on a small",
        "start": 612.96,
        "duration": 6.03
    },
    {
        "text": "number of diseases and so what you'll",
        "start": 617.19,
        "duration": 3.96
    },
    {
        "text": "see today is a presentation around the",
        "start": 618.99,
        "duration": 4.05
    },
    {
        "text": "biology of prostate cancer the biology",
        "start": 621.15,
        "duration": 4.26
    },
    {
        "text": "of lung cancer and the biology of human",
        "start": 623.04,
        "duration": 6.48
    },
    {
        "text": "logic b-cell malignancies you know this",
        "start": 625.41,
        "duration": 5.85
    },
    {
        "text": "is this is about one fifth of all",
        "start": 629.52,
        "duration": 4.26
    },
    {
        "text": "cancers but where you know so rather",
        "start": 631.26,
        "duration": 4.89
    },
    {
        "text": "than trying to develop drugs at every",
        "start": 633.78,
        "duration": 4.92
    },
    {
        "text": "therapeutic area in every opportunity in",
        "start": 636.15,
        "duration": 5.28
    },
    {
        "text": "cancer we wanted to be able to focus on",
        "start": 638.7,
        "duration": 4.98
    },
    {
        "text": "a smaller number of indications be able",
        "start": 641.43,
        "duration": 4.08
    },
    {
        "text": "to go biologically but to deeper into",
        "start": 643.68,
        "duration": 3.84
    },
    {
        "text": "those indications and then bring pool",
        "start": 645.51,
        "duration": 3.72
    },
    {
        "text": "with multiple different drugs into",
        "start": 647.52,
        "duration": 2.91
    },
    {
        "text": "meeting in different points in the",
        "start": 649.23,
        "duration": 2.91
    },
    {
        "text": "development pathway over long period of",
        "start": 650.43,
        "duration": 4.23
    },
    {
        "text": "time rather than the traditional",
        "start": 652.14,
        "duration": 4.44
    },
    {
        "text": "approaches bomber is basically you know",
        "start": 654.66,
        "duration": 4.26
    },
    {
        "text": "basic following an individual compound",
        "start": 656.58,
        "duration": 5.64
    },
    {
        "text": "and perhaps a backup at a time and then",
        "start": 658.92,
        "duration": 4.83
    },
    {
        "text": "falling at into all different",
        "start": 662.22,
        "duration": 3.42
    },
    {
        "text": "indications we wanted to basically take",
        "start": 663.75,
        "duration": 3.42
    },
    {
        "text": "an approach it down really deep into",
        "start": 665.64,
        "duration": 3.03
    },
    {
        "text": "some limited number of diseases and",
        "start": 667.17,
        "duration": 3.21
    },
    {
        "text": "becoming really expert in those areas",
        "start": 668.67,
        "duration": 3.69
    },
    {
        "text": "and this has really driven by some",
        "start": 670.38,
        "duration": 3.69
    },
    {
        "text": "underlying biology and science that will",
        "start": 672.36,
        "duration": 4.65
    },
    {
        "text": "come to in a minute so the areas we're",
        "start": 674.07,
        "duration": 5.31
    },
    {
        "text": "going to talk about today hematologic",
        "start": 677.01,
        "duration": 5.22
    },
    {
        "text": "malignancies initially thinking about",
        "start": 679.38,
        "duration": 6.12
    },
    {
        "text": "b-cell malignancies and drugs that",
        "start": 682.23,
        "duration": 9.27
    },
    {
        "text": "basically work through imbruvica here",
        "start": 685.5,
        "duration": 7.74
    },
    {
        "text": "this is the drug here this is a this is",
        "start": 691.5,
        "duration": 4.05
    },
    {
        "text": "a bruton's tyrosine kinase inhibitor",
        "start": 693.24,
        "duration": 5.19
    },
    {
        "text": "this works by blocking b-cell receptor",
        "start": 695.55,
        "duration": 4.56
    },
    {
        "text": "signaling so in essence basically the",
        "start": 698.43,
        "duration": 3.75
    },
    {
        "text": "drug worked like stopping proliferation",
        "start": 700.11,
        "duration": 5.28
    },
    {
        "text": "in a b-cell malignancies by blocking the",
        "start": 702.18,
        "duration": 5.34
    },
    {
        "text": "b-cell receptor at signaling that you",
        "start": 705.39,
        "duration": 2.78
    },
    {
        "text": "know",
        "start": 707.52,
        "duration": 5.28
    },
    {
        "text": "signaling we have Velcade as a",
        "start": 708.17,
        "duration": 8.2
    },
    {
        "text": "proteasome inhibitor you know Derek to",
        "start": 712.8,
        "duration": 5.12
    },
    {
        "text": "map here at the bottom in",
        "start": 716.37,
        "duration": 5.61
    },
    {
        "text": "cd38 anti cd38 molecule variety so",
        "start": 717.92,
        "duration": 5.92
    },
    {
        "text": "Takanawa is an anti il-6",
        "start": 721.98,
        "duration": 4.89
    },
    {
        "text": "it's a variety of different mechanisms",
        "start": 723.84,
        "duration": 6.5
    },
    {
        "text": "your EC here and b-cell malignancies",
        "start": 726.87,
        "duration": 8.51
    },
    {
        "text": "expanding into into myeloid malignancies",
        "start": 730.34,
        "duration": 7.36
    },
    {
        "text": "the other major area we'll talk about",
        "start": 735.38,
        "duration": 5.5
    },
    {
        "text": "today's and prostate cancer - - two",
        "start": 737.7,
        "duration": 7.14
    },
    {
        "text": "major drugs here Zytiga is an antigen",
        "start": 740.88,
        "duration": 6.87
    },
    {
        "text": "and and Aragon 509 about antigen",
        "start": 744.84,
        "duration": 6.93
    },
    {
        "text": "synthesis inhibitors prostate cancer is",
        "start": 747.75,
        "duration": 6.93
    },
    {
        "text": "really driven by androgen synthesis and",
        "start": 751.77,
        "duration": 4.62
    },
    {
        "text": "signaling through the androgen pathway",
        "start": 754.68,
        "duration": 4.56
    },
    {
        "text": "it's not a vastly molecular subtype",
        "start": 756.39,
        "duration": 4.59
    },
    {
        "text": "disease and all of them you know disease",
        "start": 759.24,
        "duration": 3.09
    },
    {
        "text": "progression is related",
        "start": 760.98,
        "duration": 5.31
    },
    {
        "text": "I barely through is androgen pathway and",
        "start": 762.33,
        "duration": 8.4
    },
    {
        "text": "the the current therapies in prostate",
        "start": 766.29,
        "duration": 6.48
    },
    {
        "text": "cancer all work through inhibition and",
        "start": 770.73,
        "duration": 4.38
    },
    {
        "text": "managing synthesis often in combination",
        "start": 772.77,
        "duration": 5.91
    },
    {
        "text": "with other targeted interventions but",
        "start": 775.11,
        "duration": 4.83
    },
    {
        "text": "but but the androgen",
        "start": 778.68,
        "duration": 3.75
    },
    {
        "text": "pathway is really critical is the",
        "start": 779.94,
        "duration": 4.5
    },
    {
        "text": "critical pathway for essentially all",
        "start": 782.43,
        "duration": 4.8
    },
    {
        "text": "prostate cancer lung cancer is a",
        "start": 784.44,
        "duration": 5.34
    },
    {
        "text": "contrast very much the prostate cancer",
        "start": 787.23,
        "duration": 4.71
    },
    {
        "text": "is that it is a very much more molecular",
        "start": 789.78,
        "duration": 5.82
    },
    {
        "text": "subtype of disease different subsets of",
        "start": 791.94,
        "duration": 5.58
    },
    {
        "text": "lung cancer are driven by mutations in",
        "start": 795.6,
        "duration": 8.42
    },
    {
        "text": "EGFR hey RAF Matt in a variety of other",
        "start": 797.52,
        "duration": 11.85
    },
    {
        "text": "individual molecular subtypes you know",
        "start": 804.02,
        "duration": 7.0
    },
    {
        "text": "so it's very different in the sense that",
        "start": 809.37,
        "duration": 3.3
    },
    {
        "text": "it's a highly diverse disease or",
        "start": 811.02,
        "duration": 2.94
    },
    {
        "text": "prostate cancer is a much more",
        "start": 812.67,
        "duration": 4.5
    },
    {
        "text": "homogeneous disease multiple different",
        "start": 813.96,
        "duration": 5.13
    },
    {
        "text": "approaches here to inhibition a",
        "start": 817.17,
        "duration": 3.78
    },
    {
        "text": "particular signal transduction pathways",
        "start": 819.09,
        "duration": 4.56
    },
    {
        "text": "or other approaches and increasingly",
        "start": 820.95,
        "duration": 5.58
    },
    {
        "text": "focus on immune based and what Mike will",
        "start": 823.65,
        "duration": 4.23
    },
    {
        "text": "tell you about it a lot of immunotherapy",
        "start": 826.53,
        "duration": 3.33
    },
    {
        "text": "an immune based approaches to these",
        "start": 827.88,
        "duration": 3.579
    },
    {
        "text": "diseases",
        "start": 829.86,
        "duration": 3.159
    },
    {
        "text": "and then we have emerging programs in",
        "start": 831.459,
        "duration": 4.44
    },
    {
        "text": "colorectal cancer colorectal being one",
        "start": 833.019,
        "duration": 4.8
    },
    {
        "text": "of the you know one of the most well",
        "start": 835.899,
        "duration": 3.81
    },
    {
        "text": "genomically automatically characterized",
        "start": 837.819,
        "duration": 3.99
    },
    {
        "text": "diseases but still therapeutically",
        "start": 839.709,
        "duration": 4.05
    },
    {
        "text": "someone ineffective you know data based",
        "start": 841.809,
        "duration": 3.96
    },
    {
        "text": "on that it still means somewhat you know",
        "start": 843.759,
        "duration": 5.01
    },
    {
        "text": "limited therapeutic effect so I'm you",
        "start": 845.769,
        "duration": 4.5
    },
    {
        "text": "know we have an early program in",
        "start": 848.769,
        "duration": 3.24
    },
    {
        "text": "colorectal cancer but we'll spend most",
        "start": 850.269,
        "duration": 3.271
    },
    {
        "text": "of the presentation talking to you about",
        "start": 852.009,
        "duration": 4.77
    },
    {
        "text": "the biology and computational aspects of",
        "start": 853.54,
        "duration": 6.169
    },
    {
        "text": "interpreting the biology direct response",
        "start": 856.779,
        "duration": 6.72
    },
    {
        "text": "emergence of drug resistance in human",
        "start": 859.709,
        "duration": 5.23
    },
    {
        "text": "logic malignancies in prostate cancer",
        "start": 863.499,
        "duration": 4.161
    },
    {
        "text": "and lung cancer",
        "start": 864.939,
        "duration": 2.721
    },
    {
        "text": "just to you know someone you know just",
        "start": 868.749,
        "duration": 3.15
    },
    {
        "text": "to give you some of the diversity of the",
        "start": 870.61,
        "duration": 3.539
    },
    {
        "text": "types of drugs that we we see and when",
        "start": 871.899,
        "duration": 5.61
    },
    {
        "text": "we work on our team Imam is an anti cd38",
        "start": 874.149,
        "duration": 8.16
    },
    {
        "text": "it's a monoclonal antibody ibrutinib is",
        "start": 877.509,
        "duration": 8.31
    },
    {
        "text": "a irreversible bruton's tyrosine kinase",
        "start": 882.309,
        "duration": 6.84
    },
    {
        "text": "inhibitor it's unusual for small",
        "start": 885.819,
        "duration": 5.37
    },
    {
        "text": "molecule to be irreversibly binding",
        "start": 889.149,
        "duration": 4.68
    },
    {
        "text": "because of the potential toxicities from",
        "start": 891.189,
        "duration": 4.231
    },
    {
        "text": "that irreversible binding but in this",
        "start": 893.829,
        "duration": 4.081
    },
    {
        "text": "case it would be quite manageable",
        "start": 895.42,
        "duration": 6.93
    },
    {
        "text": "Zytiga is a bandage and synthesis",
        "start": 897.91,
        "duration": 10.94
    },
    {
        "text": "inhibitor so toxin AB is an anti il-6 a",
        "start": 902.35,
        "duration": 10.079
    },
    {
        "text": "monoclonal antibody that prevents the",
        "start": 908.85,
        "duration": 6.849
    },
    {
        "text": "team of getting access to il-6 Velcade a",
        "start": 912.429,
        "duration": 6.061
    },
    {
        "text": "proteasome inhibitor 5:09 is another",
        "start": 915.699,
        "duration": 6.42
    },
    {
        "text": "antigen antagonist and in synthesis",
        "start": 918.49,
        "duration": 7.98
    },
    {
        "text": "antagonists and the fgf program is this",
        "start": 922.119,
        "duration": 6.181
    },
    {
        "text": "is a small molecule tyrosine kinase",
        "start": 926.47,
        "duration": 6.229
    },
    {
        "text": "inhibitor this is a Nana mola han fgfr",
        "start": 928.3,
        "duration": 8.55
    },
    {
        "text": "inhibitor so there are actually four fgf",
        "start": 932.699,
        "duration": 7.45
    },
    {
        "text": "receptor inhibited in the genome more",
        "start": 936.85,
        "duration": 5.25
    },
    {
        "text": "than 20 different ligands that bind to",
        "start": 940.149,
        "duration": 5.1
    },
    {
        "text": "those or receptors and so this is a drug",
        "start": 942.1,
        "duration": 5.609
    },
    {
        "text": "that actually inhibits the signaling out",
        "start": 945.249,
        "duration": 5.34
    },
    {
        "text": "of the fgf receptor for the receptors",
        "start": 947.709,
        "duration": 5.07
    },
    {
        "text": "and this is an interesting program Mike",
        "start": 950.589,
        "duration": 3.511
    },
    {
        "text": "will tell you about where we're actually",
        "start": 952.779,
        "duration": 3.511
    },
    {
        "text": "developing a companion diagnostic around",
        "start": 954.1,
        "duration": 4.529
    },
    {
        "text": "mutations in the gene to determine who",
        "start": 956.29,
        "duration": 5.339
    },
    {
        "text": "you know which the therapy with an anti",
        "start": 958.629,
        "duration": 4.56
    },
    {
        "text": "yep except if you have the wild-type",
        "start": 961.629,
        "duration": 3.63
    },
    {
        "text": "sequence then you don't you know then",
        "start": 963.189,
        "duration": 4.051
    },
    {
        "text": "telling you that your FD ever set the",
        "start": 965.259,
        "duration": 5.01
    },
    {
        "text": "clock wake is not activated and the cell",
        "start": 967.24,
        "duration": 5.279
    },
    {
        "text": "is not driving its proliferation through",
        "start": 970.269,
        "duration": 3.87
    },
    {
        "text": "the title of their olfactory receptor",
        "start": 972.519,
        "duration": 3.42
    },
    {
        "text": "but it's using other pathways to drive",
        "start": 974.139,
        "duration": 4.29
    },
    {
        "text": "it for liberation so you can imagine if",
        "start": 975.939,
        "duration": 5.221
    },
    {
        "text": "you then try to inhibit FGFR the patient",
        "start": 978.429,
        "duration": 4.2
    },
    {
        "text": "who is inactivated you can have no",
        "start": 981.16,
        "duration": 3.63
    },
    {
        "text": "therapeutic benefit so this is a nice",
        "start": 982.629,
        "duration": 4.68
    },
    {
        "text": "canonical example of using a diagnostic",
        "start": 984.79,
        "duration": 5.07
    },
    {
        "text": "test for the driver mutation to identify",
        "start": 987.309,
        "duration": 5.701
    },
    {
        "text": "patients will respond the therapy",
        "start": 989.86,
        "duration": 7.11
    },
    {
        "text": "and so let me skip over this one in the",
        "start": 993.01,
        "duration": 6.03
    },
    {
        "text": "interest of time a big part of what we",
        "start": 996.97,
        "duration": 3.33
    },
    {
        "text": "end up having to do of course is",
        "start": 999.04,
        "duration": 3.03
    },
    {
        "text": "basically finally the predictive",
        "start": 1000.3,
        "duration": 3.719
    },
    {
        "text": "biomarkers in our drug development",
        "start": 1002.07,
        "duration": 3.87
    },
    {
        "text": "program and then develop a regulatory",
        "start": 1004.019,
        "duration": 4.26
    },
    {
        "text": "approval companion diagnostic test and",
        "start": 1005.94,
        "duration": 4.139
    },
    {
        "text": "so when we refer to a companion",
        "start": 1008.279,
        "duration": 3.901
    },
    {
        "text": "diagnostic test we be it is a particular",
        "start": 1010.079,
        "duration": 4.831
    },
    {
        "text": "assay that's been approved by the FDA it",
        "start": 1012.18,
        "duration": 4.38
    },
    {
        "text": "actually allows you to predict response",
        "start": 1014.91,
        "duration": 3.9
    },
    {
        "text": "to therapy and today there are only 19",
        "start": 1016.56,
        "duration": 3.959
    },
    {
        "text": "of movies that would be approved by the",
        "start": 1018.81,
        "duration": 4.11
    },
    {
        "text": "FDA but they're there they're all again",
        "start": 1020.519,
        "duration": 8.701
    },
    {
        "text": "tyrosine kinase a small number of TPS we",
        "start": 1022.92,
        "duration": 7.499
    },
    {
        "text": "also have a lot of interest in one",
        "start": 1029.22,
        "duration": 2.88
    },
    {
        "text": "things merging around translational",
        "start": 1030.419,
        "duration": 2.91
    },
    {
        "text": "research one of the things we're really",
        "start": 1032.1,
        "duration": 3.03
    },
    {
        "text": "interested in doing is looking at",
        "start": 1033.329,
        "duration": 4.86
    },
    {
        "text": "circulating tumor cells so that we can",
        "start": 1035.13,
        "duration": 5.1
    },
    {
        "text": "actually monitor the molecular changes",
        "start": 1038.189,
        "duration": 3.781
    },
    {
        "text": "going on in tema throughout that course",
        "start": 1040.23,
        "duration": 3.66
    },
    {
        "text": "of disease it's typically a patient when",
        "start": 1041.97,
        "duration": 4.079
    },
    {
        "text": "presented with cancer they'll have a",
        "start": 1043.89,
        "duration": 4.439
    },
    {
        "text": "diagnostic biopsy taken at the time of",
        "start": 1046.049,
        "duration": 5.281
    },
    {
        "text": "diagnosis that is usually the only",
        "start": 1048.329,
        "duration": 4.801
    },
    {
        "text": "physical sample that will be taken from",
        "start": 1051.33,
        "duration": 3.03
    },
    {
        "text": "a patient during that course of",
        "start": 1053.13,
        "duration": 3.0
    },
    {
        "text": "treatment they usually will not be",
        "start": 1054.36,
        "duration": 3.66
    },
    {
        "text": "recycled unless they're in a major",
        "start": 1056.13,
        "duration": 4.679
    },
    {
        "text": "research institution but typically in",
        "start": 1058.02,
        "duration": 4.22
    },
    {
        "text": "the course of treatment a patient is",
        "start": 1060.809,
        "duration": 3.87
    },
    {
        "text": "Canter's only sampled once during the",
        "start": 1062.24,
        "duration": 4.78
    },
    {
        "text": "course of disease and we know of course",
        "start": 1064.679,
        "duration": 4.651
    },
    {
        "text": "that over time the Timur evolved the",
        "start": 1067.02,
        "duration": 4.62
    },
    {
        "text": "different somatic mutations emerge they",
        "start": 1069.33,
        "duration": 3.75
    },
    {
        "text": "get their different selection pressure",
        "start": 1071.64,
        "duration": 3.24
    },
    {
        "text": "imposed by therapy by disease",
        "start": 1073.08,
        "duration": 4.38
    },
    {
        "text": "progression in the patient and so one of",
        "start": 1074.88,
        "duration": 3.84
    },
    {
        "text": "the things we want to be able to do is",
        "start": 1077.46,
        "duration": 3.18
    },
    {
        "text": "to be able to look in real time and the",
        "start": 1078.72,
        "duration": 3.449
    },
    {
        "text": "molecular changes are occurring in the",
        "start": 1080.64,
        "duration": 3.99
    },
    {
        "text": "tumor and adjust the therapy based on",
        "start": 1082.169,
        "duration": 4.801
    },
    {
        "text": "what they're today as opposed to what",
        "start": 1084.63,
        "duration": 4.02
    },
    {
        "text": "with maybe they're in the diagnostic",
        "start": 1086.97,
        "duration": 3.24
    },
    {
        "text": "plot was commanding taken months or",
        "start": 1088.65,
        "duration": 4.05
    },
    {
        "text": "years before Billy and the team will",
        "start": 1090.21,
        "duration": 4.86
    },
    {
        "text": "City subsequently have evolved so",
        "start": 1092.7,
        "duration": 4.2
    },
    {
        "text": "there's a lot of interest in looking at",
        "start": 1095.07,
        "duration": 4.02
    },
    {
        "text": "both circulating tumor cells also",
        "start": 1096.9,
        "duration": 3.87
    },
    {
        "text": "looking at the content of the tumor that",
        "start": 1099.09,
        "duration": 5.15
    },
    {
        "text": "may be from from ourselves",
        "start": 1100.77,
        "duration": 6.27
    },
    {
        "text": "you know the state from the tumor in",
        "start": 1104.24,
        "duration": 4.33
    },
    {
        "text": "looking at the RNA and their DNA",
        "start": 1107.04,
        "duration": 4.47
    },
    {
        "text": "particularly DNA you know in circulating",
        "start": 1108.57,
        "duration": 5.79
    },
    {
        "text": "in blood and plasma and being able to",
        "start": 1111.51,
        "duration": 5.28
    },
    {
        "text": "differentiate DNA from normal cells from",
        "start": 1114.36,
        "duration": 4.47
    },
    {
        "text": "cell to the aiport Otacon a chronic and",
        "start": 1116.79,
        "duration": 4.05
    },
    {
        "text": "a released Hema cell DNA into the",
        "start": 1118.83,
        "duration": 3.839
    },
    {
        "text": "circulation they own a major driver",
        "start": 1120.84,
        "duration": 3.39
    },
    {
        "text": "mutations and things like that directly",
        "start": 1122.669,
        "duration": 2.981
    },
    {
        "text": "from the plasma",
        "start": 1124.23,
        "duration": 3.1
    },
    {
        "text": "but also here's an example of looking at",
        "start": 1125.65,
        "duration": 3.9
    },
    {
        "text": "tumor cells from the blood looking here",
        "start": 1127.33,
        "duration": 3.42
    },
    {
        "text": "to you and this is looking at gene",
        "start": 1129.55,
        "duration": 2.97
    },
    {
        "text": "application using a fluorescence that",
        "start": 1130.75,
        "duration": 4.44
    },
    {
        "text": "you add analysis of circulating tumor",
        "start": 1132.52,
        "duration": 6.81
    },
    {
        "text": "cell again we're also involved in",
        "start": 1135.19,
        "duration": 8.22
    },
    {
        "text": "developing novel genomic and cellular",
        "start": 1139.33,
        "duration": 5.67
    },
    {
        "text": "technology this is a microfluidic",
        "start": 1143.41,
        "duration": 3.39
    },
    {
        "text": "approach to the separation of",
        "start": 1145.0,
        "duration": 4.22
    },
    {
        "text": "circulating tumor cells out of the blood",
        "start": 1146.8,
        "duration": 5.31
    },
    {
        "text": "I won't go into detail on this but this",
        "start": 1149.22,
        "duration": 4.21
    },
    {
        "text": "is some of the other things that we do",
        "start": 1152.11,
        "duration": 2.82
    },
    {
        "text": "that's where we could basically take a",
        "start": 1153.43,
        "duration": 3.81
    },
    {
        "text": "seven-and-a-half ml blood draw and then",
        "start": 1154.93,
        "duration": 4.65
    },
    {
        "text": "isolate a few ten to hundreds of ctc's",
        "start": 1157.24,
        "duration": 3.84
    },
    {
        "text": "out of that blood and then be able to",
        "start": 1159.58,
        "duration": 3.54
    },
    {
        "text": "them to analyze those at individual",
        "start": 1161.08,
        "duration": 5.25
    },
    {
        "text": "cells or cool them and do next-gen",
        "start": 1163.12,
        "duration": 5.25
    },
    {
        "text": "sequencing based approaches through the",
        "start": 1166.33,
        "duration": 3.33
    },
    {
        "text": "characterization and the team is",
        "start": 1168.37,
        "duration": 3.21
    },
    {
        "text": "directly from the blood without the",
        "start": 1169.66,
        "duration": 3.33
    },
    {
        "text": "requirement of meaning to do an invasive",
        "start": 1171.58,
        "duration": 7.8
    },
    {
        "text": "procedure for the patient and then",
        "start": 1172.99,
        "duration": 8.16
    },
    {
        "text": "just imagine the immunotherapy strategy",
        "start": 1179.38,
        "duration": 4.23
    },
    {
        "text": "one of the big changes that's happening",
        "start": 1181.15,
        "duration": 4.98
    },
    {
        "text": "in the industry right now is an",
        "start": 1183.61,
        "duration": 5.34
    },
    {
        "text": "increased boat that's on immunotherapy",
        "start": 1186.13,
        "duration": 5.79
    },
    {
        "text": "and this is really being driven by",
        "start": 1188.95,
        "duration": 5.28
    },
    {
        "text": "recent data that's emerged over the last",
        "start": 1191.92,
        "duration": 6.0
    },
    {
        "text": "you know three four years around being",
        "start": 1194.23,
        "duration": 7.89
    },
    {
        "text": "able to inhibit immune checkpoint so for",
        "start": 1197.92,
        "duration": 7.41
    },
    {
        "text": "those of you not familiar with it an",
        "start": 1202.12,
        "duration": 5.58
    },
    {
        "text": "immune checkpoint essentially is a",
        "start": 1205.33,
        "duration": 4.38
    },
    {
        "text": "ligand that is expressed on the surface",
        "start": 1207.7,
        "duration": 5.67
    },
    {
        "text": "of a tumor cell that actually inhibits",
        "start": 1209.71,
        "duration": 5.67
    },
    {
        "text": "the T cell response to the tumor and",
        "start": 1213.37,
        "duration": 3.93
    },
    {
        "text": "prevents the team of the T cell from",
        "start": 1215.38,
        "duration": 6.0
    },
    {
        "text": "recognizing the cell is fine so in",
        "start": 1217.3,
        "duration": 6.24
    },
    {
        "text": "essence you know what seems to happens",
        "start": 1221.38,
        "duration": 5.61
    },
    {
        "text": "in this biology is that if you know that",
        "start": 1223.54,
        "duration": 6.36
    },
    {
        "text": "the chemo cell essentially is cloaking",
        "start": 1226.99,
        "duration": 4.5
    },
    {
        "text": "itself it's hiding from the immune",
        "start": 1229.9,
        "duration": 3.72
    },
    {
        "text": "system and preventing the T cell T cell",
        "start": 1231.49,
        "duration": 6.78
    },
    {
        "text": "based respond to the tumor and so what",
        "start": 1233.62,
        "duration": 6.84
    },
    {
        "text": "was developed with these drugs you know",
        "start": 1238.27,
        "duration": 4.92
    },
    {
        "text": "for the ctla-4 and the pd-1 checkpoints",
        "start": 1240.46,
        "duration": 6.81
    },
    {
        "text": "is a means of inhibiting this so in",
        "start": 1243.19,
        "duration": 5.76
    },
    {
        "text": "absence what happens is that when you",
        "start": 1247.27,
        "duration": 3.51
    },
    {
        "text": "inhibit down in a patient who's had a",
        "start": 1248.95,
        "duration": 4.29
    },
    {
        "text": "tumor with a prior immune response that",
        "start": 1250.78,
        "duration": 4.02
    },
    {
        "text": "prior immune response in reestablishing",
        "start": 1253.24,
        "duration": 4.83
    },
    {
        "text": "so and it's and what's been found is it",
        "start": 1254.8,
        "duration": 5.4
    },
    {
        "text": "in a subset of patient we can",
        "start": 1258.07,
        "duration": 5.07
    },
    {
        "text": "essentially have very very long term",
        "start": 1260.2,
        "duration": 4.77
    },
    {
        "text": "outcome survival benefit to patients",
        "start": 1263.14,
        "duration": 4.23
    },
    {
        "text": "essentially cure these patients called",
        "start": 1264.97,
        "duration": 4.8
    },
    {
        "text": "their disease through the the immune",
        "start": 1267.37,
        "duration": 6.54
    },
    {
        "text": "response so there there's now numerous",
        "start": 1269.77,
        "duration": 6.42
    },
    {
        "text": "data on patients surviving five or more",
        "start": 1273.91,
        "duration": 5.28
    },
    {
        "text": "years post therapy who previously had",
        "start": 1276.19,
        "duration": 5.07
    },
    {
        "text": "stage four melanoma so Stage four",
        "start": 1279.19,
        "duration": 3.93
    },
    {
        "text": "melanoma patient you would expect to",
        "start": 1281.26,
        "duration": 3.56
    },
    {
        "text": "have a life expectancy measured in weeks",
        "start": 1283.12,
        "duration": 4.44
    },
    {
        "text": "there's a very late stage melanoma but",
        "start": 1284.82,
        "duration": 5.47
    },
    {
        "text": "absolutely lethal disease but now by",
        "start": 1287.56,
        "duration": 5.25
    },
    {
        "text": "basically using this pd-1 blockade",
        "start": 1290.29,
        "duration": 4.8
    },
    {
        "text": "you've been able to re-establish the",
        "start": 1292.81,
        "duration": 3.96
    },
    {
        "text": "immune response and so now so about",
        "start": 1295.09,
        "duration": 3.45
    },
    {
        "text": "twenty to fifty to twenty percent of",
        "start": 1296.77,
        "duration": 4.38
    },
    {
        "text": "melanoma patients can now be essentially",
        "start": 1298.54,
        "duration": 5.16
    },
    {
        "text": "cured of their disease by these immune",
        "start": 1301.15,
        "duration": 4.59
    },
    {
        "text": "based therapies and what we're trying to",
        "start": 1303.7,
        "duration": 3.99
    },
    {
        "text": "understand is what is happening to those",
        "start": 1305.74,
        "duration": 3.72
    },
    {
        "text": "patients you have this really cool long",
        "start": 1307.69,
        "duration": 4.4
    },
    {
        "text": "survival you should have you know",
        "start": 1309.46,
        "duration": 4.079
    },
    {
        "text": "statistically die",
        "start": 1312.09,
        "duration": 2.789
    },
    {
        "text": "within a matter of weeks or months",
        "start": 1313.539,
        "duration": 3.541
    },
    {
        "text": "because of the late stage of the disease",
        "start": 1314.879,
        "duration": 3.91
    },
    {
        "text": "yet they're now surviving treatment",
        "start": 1317.08,
        "duration": 5.37
    },
    {
        "text": "disease three years after aqua therapy",
        "start": 1318.789,
        "duration": 5.94
    },
    {
        "text": "and the hope is to be able to take these",
        "start": 1322.45,
        "duration": 4.14
    },
    {
        "text": "long-term immune responses and actually",
        "start": 1324.729,
        "duration": 3.39
    },
    {
        "text": "you know so now instead of being able",
        "start": 1326.59,
        "duration": 3.029
    },
    {
        "text": "just to ground at work with a minority",
        "start": 1328.119,
        "duration": 3.15
    },
    {
        "text": "of patients be able to understand the",
        "start": 1329.619,
        "duration": 3.06
    },
    {
        "text": "immune system and the biology of the",
        "start": 1331.269,
        "duration": 4.47
    },
    {
        "text": "tumor and one of the internet with the",
        "start": 1332.679,
        "duration": 4.531
    },
    {
        "text": "paper published that he was in science",
        "start": 1335.739,
        "duration": 3.361
    },
    {
        "text": "Mike was it with the sir yes they would",
        "start": 1337.21,
        "duration": 3.419
    },
    {
        "text": "sort underlying the hypothesis is that",
        "start": 1339.1,
        "duration": 4.5
    },
    {
        "text": "the mutational status of the team so you",
        "start": 1340.629,
        "duration": 4.74
    },
    {
        "text": "can imagine as the team is develop their",
        "start": 1343.6,
        "duration": 5.22
    },
    {
        "text": "somatic mutations in through the genomic",
        "start": 1345.369,
        "duration": 5.28
    },
    {
        "text": "instability of the tumor and if those",
        "start": 1348.82,
        "duration": 4.079
    },
    {
        "text": "then mutations with any you know",
        "start": 1350.649,
        "duration": 3.77
    },
    {
        "text": "converted into RNA",
        "start": 1352.899,
        "duration": 3.87
    },
    {
        "text": "transcribe you know and translated into",
        "start": 1354.419,
        "duration": 5.35
    },
    {
        "text": "protein but those mutations now create",
        "start": 1356.769,
        "duration": 5.28
    },
    {
        "text": "neo antigens you have novel proteins",
        "start": 1359.769,
        "duration": 4.951
    },
    {
        "text": "with mutations and those are being",
        "start": 1362.049,
        "duration": 4.651
    },
    {
        "text": "recognized as a neo epitope for the",
        "start": 1364.72,
        "duration": 4.589
    },
    {
        "text": "immune system to recognize and so the",
        "start": 1366.7,
        "duration": 4.679
    },
    {
        "text": "theory that submerging is is the somatic",
        "start": 1369.309,
        "duration": 4.2
    },
    {
        "text": "instability is creating the production",
        "start": 1371.379,
        "duration": 3.9
    },
    {
        "text": "of more and more neo epic up on these",
        "start": 1373.509,
        "duration": 3.54
    },
    {
        "text": "schemas through the somatic mutation",
        "start": 1375.279,
        "duration": 4.291
    },
    {
        "text": "that makes the cell more visible to the",
        "start": 1377.049,
        "duration": 4.71
    },
    {
        "text": "immune system so this has to be borne",
        "start": 1379.57,
        "duration": 4.799
    },
    {
        "text": "out but it's an interesting idea of why",
        "start": 1381.759,
        "duration": 4.681
    },
    {
        "text": "some cells are more energetic than",
        "start": 1384.369,
        "duration": 3.42
    },
    {
        "text": "others in terms of the number commute",
        "start": 1386.44,
        "duration": 3.0
    },
    {
        "text": "aces they're carrying and which of those",
        "start": 1387.789,
        "duration": 3.661
    },
    {
        "text": "are actually carry you know inverted",
        "start": 1389.44,
        "duration": 6.02
    },
    {
        "text": "into breast is broken",
        "start": 1391.45,
        "duration": 4.01
    },
    {
        "text": "other areas are looking at it you know",
        "start": 1395.86,
        "duration": 3.36
    },
    {
        "text": "one of the areas another exciting area",
        "start": 1397.39,
        "duration": 4.11
    },
    {
        "text": "about immunology is looking at measuring",
        "start": 1399.22,
        "duration": 4.26
    },
    {
        "text": "T cell infiltration and the teamwork you",
        "start": 1401.5,
        "duration": 3.9
    },
    {
        "text": "find patients you have an active immune",
        "start": 1403.48,
        "duration": 3.87
    },
    {
        "text": "response we can detect he self within",
        "start": 1405.4,
        "duration": 3.72
    },
    {
        "text": "their team ur that are essentially",
        "start": 1407.35,
        "duration": 5.13
    },
    {
        "text": "located close to the team itself and and",
        "start": 1409.12,
        "duration": 5.73
    },
    {
        "text": "are essentially killing those teams so",
        "start": 1412.48,
        "duration": 4.77
    },
    {
        "text": "it's by developing by specific",
        "start": 1414.85,
        "duration": 4.08
    },
    {
        "text": "antibodies we can put that we can have",
        "start": 1417.25,
        "duration": 3.57
    },
    {
        "text": "one of the you know so on instead of",
        "start": 1418.93,
        "duration": 4.23
    },
    {
        "text": "having an antibody that only binds to",
        "start": 1420.82,
        "duration": 4.47
    },
    {
        "text": "one motif you know by specific antibody",
        "start": 1423.16,
        "duration": 4.65
    },
    {
        "text": "if you identify one on the surface of a",
        "start": 1425.29,
        "duration": 4.2
    },
    {
        "text": "t-cell one on the surface of the tumor",
        "start": 1427.81,
        "duration": 3.99
    },
    {
        "text": "and you can now start to bring and force",
        "start": 1429.49,
        "duration": 3.81
    },
    {
        "text": "T cells and humans and be closer",
        "start": 1431.8,
        "duration": 4.11
    },
    {
        "text": "proximity and accelerated self killing",
        "start": 1433.3,
        "duration": 4.65
    },
    {
        "text": "and you can look at multispectral",
        "start": 1435.91,
        "duration": 3.69
    },
    {
        "text": "imaging it basically looking at T cell",
        "start": 1437.95,
        "duration": 3.51
    },
    {
        "text": "infiltration and finding ways and then",
        "start": 1439.6,
        "duration": 3.42
    },
    {
        "text": "measuring way that we can show that the",
        "start": 1441.46,
        "duration": 6.24
    },
    {
        "text": "T cell to be more active within and then",
        "start": 1443.02,
        "duration": 7.11
    },
    {
        "text": "lastly this is my last slide we do an",
        "start": 1447.7,
        "duration": 4.23
    },
    {
        "text": "awful lot of work of collaboration",
        "start": 1450.13,
        "duration": 3.84
    },
    {
        "text": "this is busy this is a very small number",
        "start": 1451.93,
        "duration": 4.71
    },
    {
        "text": "of you know but you know working with a",
        "start": 1453.97,
        "duration": 4.53
    },
    {
        "text": "lot of academic institutions a lot of",
        "start": 1456.64,
        "duration": 4.2
    },
    {
        "text": "small biotech companies in developing",
        "start": 1458.5,
        "duration": 3.93
    },
    {
        "text": "these different technologies and",
        "start": 1460.84,
        "duration": 4.62
    },
    {
        "text": "approaches belper is instituted in",
        "start": 1462.43,
        "duration": 6.09
    },
    {
        "text": "Boston and Harvard",
        "start": 1465.46,
        "duration": 5.64
    },
    {
        "text": "MD Anderson we have collaborations with",
        "start": 1468.52,
        "duration": 4.41
    },
    {
        "text": "any other you know that we actually you",
        "start": 1471.1,
        "duration": 3.81
    },
    {
        "text": "know today meeting with people today we",
        "start": 1472.93,
        "duration": 5.82
    },
    {
        "text": "have several collaborations well but",
        "start": 1474.91,
        "duration": 5.13
    },
    {
        "text": "there's probably a list of about 20",
        "start": 1478.75,
        "duration": 3.33
    },
    {
        "text": "different academic senate that we",
        "start": 1480.04,
        "duration": 4.47
    },
    {
        "text": "collaborate with you know for these",
        "start": 1482.08,
        "duration": 4.74
    },
    {
        "text": "types of approaches so I'm gonna turn it",
        "start": 1484.51,
        "duration": 6.51
    },
    {
        "text": "over now to Mike and have him basically",
        "start": 1486.82,
        "duration": 6.6
    },
    {
        "text": "give you a more detailed perspective on",
        "start": 1491.02,
        "duration": 4.08
    },
    {
        "text": "some of these programs specifically",
        "start": 1493.42,
        "duration": 3.15
    },
    {
        "text": "referring to the biology in the",
        "start": 1495.1,
        "duration": 3.6
    },
    {
        "text": "processes of drug development you know",
        "start": 1496.57,
        "duration": 5.06
    },
    {
        "text": "in these different programs",
        "start": 1498.7,
        "duration": 2.93
    },
    {
        "text": "that works here we okay all right so I",
        "start": 1513.61,
        "duration": 7.75
    },
    {
        "text": "I'll start with a brief introduction so",
        "start": 1519.23,
        "duration": 6.6
    },
    {
        "text": "I have a bioinformatics background but I",
        "start": 1521.36,
        "duration": 7.71
    },
    {
        "text": "consider myself a biologist so my",
        "start": 1525.83,
        "duration": 7.61
    },
    {
        "text": "undergrad training is in biology and",
        "start": 1529.07,
        "duration": 6.69
    },
    {
        "text": "after undergrad I actually had the",
        "start": 1533.44,
        "duration": 5.98
    },
    {
        "text": "opportunity to work at coupon for a",
        "start": 1535.76,
        "duration": 5.52
    },
    {
        "text": "group that was actually generating",
        "start": 1539.42,
        "duration": 4.88
    },
    {
        "text": "assays to detect foodborne pathogens and",
        "start": 1541.28,
        "duration": 7.2
    },
    {
        "text": "so in that process I was exposed to some",
        "start": 1544.3,
        "duration": 5.59
    },
    {
        "text": "of the research fellows there that were",
        "start": 1548.48,
        "duration": 3.75
    },
    {
        "text": "generating computational model of the",
        "start": 1549.89,
        "duration": 5.13
    },
    {
        "text": "data that we were generating and I",
        "start": 1552.23,
        "duration": 5.4
    },
    {
        "text": "actually got to know some of this work",
        "start": 1555.02,
        "duration": 4.53
    },
    {
        "text": "quite intimately and ended up",
        "start": 1557.63,
        "duration": 4.44
    },
    {
        "text": "programming some of the some of the",
        "start": 1559.55,
        "duration": 5.07
    },
    {
        "text": "software to do some of the detection and",
        "start": 1562.07,
        "duration": 5.04
    },
    {
        "text": "this actually led me to the",
        "start": 1564.62,
        "duration": 4.05
    },
    {
        "text": "bioinformatics program at Boston",
        "start": 1567.11,
        "duration": 3.63
    },
    {
        "text": "University through the prompting of some",
        "start": 1568.67,
        "duration": 3.09
    },
    {
        "text": "of the people I was working with that",
        "start": 1570.74,
        "duration": 4.35
    },
    {
        "text": "coupon and then from there I ended up",
        "start": 1571.76,
        "duration": 7.08
    },
    {
        "text": "advisor after I received my PhD and then",
        "start": 1575.09,
        "duration": 5.73
    },
    {
        "text": "a few years later well several years",
        "start": 1578.84,
        "duration": 4.14
    },
    {
        "text": "later I ended up at Johnson & Johnson",
        "start": 1580.82,
        "duration": 4.62
    },
    {
        "text": "within the Hansen group and so now I",
        "start": 1582.98,
        "duration": 5.58
    },
    {
        "text": "lead a group that those computational",
        "start": 1585.44,
        "duration": 6.03
    },
    {
        "text": "biology under Nick in the translational",
        "start": 1588.56,
        "duration": 5.25
    },
    {
        "text": "research organization and I'm just going",
        "start": 1591.47,
        "duration": 3.69
    },
    {
        "text": "to go through as Nick mentioned some of",
        "start": 1593.81,
        "duration": 2.94
    },
    {
        "text": "the projects that were involved with I'm",
        "start": 1595.16,
        "duration": 4.01
    },
    {
        "text": "not going to go through too much of the",
        "start": 1596.75,
        "duration": 5.25
    },
    {
        "text": "details of these projects I'm happy to",
        "start": 1599.17,
        "duration": 4.57
    },
    {
        "text": "talk with any of you afterwards who are",
        "start": 1602.0,
        "duration": 5.55
    },
    {
        "text": "by email later but I just wanted to give",
        "start": 1603.74,
        "duration": 4.98
    },
    {
        "text": "you a flavor of some of the projects",
        "start": 1607.55,
        "duration": 2.82
    },
    {
        "text": "we're involved with and it really",
        "start": 1608.72,
        "duration": 3.36
    },
    {
        "text": "exposure to some of the things we do in",
        "start": 1610.37,
        "duration": 4.14
    },
    {
        "text": "pharma is oftentimes if you don't have",
        "start": 1612.08,
        "duration": 4.26
    },
    {
        "text": "these types of interactions it's hard to",
        "start": 1614.51,
        "duration": 4.08
    },
    {
        "text": "understand sometimes what it is that we",
        "start": 1616.34,
        "duration": 4.95
    },
    {
        "text": "do exactly and how computational biology",
        "start": 1618.59,
        "duration": 5.73
    },
    {
        "text": "or bioinformatics actually fits in but",
        "start": 1621.29,
        "duration": 4.35
    },
    {
        "text": "I'll start with saying that it's a it's",
        "start": 1624.32,
        "duration": 4.08
    },
    {
        "text": "a critical piece of what we do and it",
        "start": 1625.64,
        "duration": 4.41
    },
    {
        "text": "really is necessary for many of the",
        "start": 1628.4,
        "duration": 4.62
    },
    {
        "text": "facets of drug discovery and also in the",
        "start": 1630.05,
        "duration": 5.05
    },
    {
        "text": "translational research project",
        "start": 1633.02,
        "duration": 4.33
    },
    {
        "text": "so as Nick mentioned we we partitioned",
        "start": 1635.1,
        "duration": 3.929
    },
    {
        "text": "ourselves into the disease area",
        "start": 1637.35,
        "duration": 4.799
    },
    {
        "text": "stronghold and really this was an effort",
        "start": 1639.029,
        "duration": 5.341
    },
    {
        "text": "to focus the group focus the entire",
        "start": 1642.149,
        "duration": 5.551
    },
    {
        "text": "entire oncology therapeutic area into",
        "start": 1644.37,
        "duration": 5.519
    },
    {
        "text": "very specific segments so as Nick",
        "start": 1647.7,
        "duration": 5.339
    },
    {
        "text": "mentioned we have a heme - we have lung",
        "start": 1649.889,
        "duration": 5.88
    },
    {
        "text": "- a prostate that and then an emerging",
        "start": 1653.039,
        "duration": 6.27
    },
    {
        "text": "emerging colorectal data and each one of",
        "start": 1655.769,
        "duration": 6.12
    },
    {
        "text": "these gases is composed of members from",
        "start": 1659.309,
        "duration": 5.1
    },
    {
        "text": "different groups including discovery our",
        "start": 1661.889,
        "duration": 5.311
    },
    {
        "text": "group translational research clinical",
        "start": 1664.409,
        "duration": 5.88
    },
    {
        "text": "commercial and others and in addition to",
        "start": 1667.2,
        "duration": 5.16
    },
    {
        "text": "that we have computational biology",
        "start": 1670.289,
        "duration": 4.74
    },
    {
        "text": "support from my group embedded within",
        "start": 1672.36,
        "duration": 5.039
    },
    {
        "text": "these within these groups so these",
        "start": 1675.029,
        "duration": 4.38
    },
    {
        "text": "groups drive a lot of the scientific",
        "start": 1677.399,
        "duration": 5.071
    },
    {
        "text": "strategy but also feeding into them are",
        "start": 1679.409,
        "duration": 7.711
    },
    {
        "text": "the clinical program so as Nick",
        "start": 1682.47,
        "duration": 6.449
    },
    {
        "text": "mentioned some of the programs within",
        "start": 1687.12,
        "duration": 4.38
    },
    {
        "text": "the heme - including ibrutinib and Derek",
        "start": 1688.919,
        "duration": 4.5
    },
    {
        "text": "- map a lot of the discussions around",
        "start": 1691.5,
        "duration": 4.529
    },
    {
        "text": "those drugs occurred within these gases",
        "start": 1693.419,
        "duration": 5.1
    },
    {
        "text": "so this allows the disease area",
        "start": 1696.029,
        "duration": 5.581
    },
    {
        "text": "stronghold to feedback and you know get",
        "start": 1698.519,
        "duration": 4.201
    },
    {
        "text": "a better understanding of what we're",
        "start": 1701.61,
        "duration": 5.73
    },
    {
        "text": "learning from the clinical study so to",
        "start": 1702.72,
        "duration": 6.9
    },
    {
        "text": "speak specifically to the computational",
        "start": 1707.34,
        "duration": 4.049
    },
    {
        "text": "biology core functions and how we",
        "start": 1709.62,
        "duration": 7.559
    },
    {
        "text": "operate within the PA were we integrate",
        "start": 1711.389,
        "duration": 7.951
    },
    {
        "text": "all the - strategies as I mentioned and",
        "start": 1717.179,
        "duration": 4.531
    },
    {
        "text": "our goals are to identify exploratory",
        "start": 1719.34,
        "duration": 5.13
    },
    {
        "text": "biomarkers and validate proposed",
        "start": 1721.71,
        "duration": 5.13
    },
    {
        "text": "predictive signatures and others that we",
        "start": 1724.47,
        "duration": 4.049
    },
    {
        "text": "may come across either in the literature",
        "start": 1726.84,
        "duration": 5.25
    },
    {
        "text": "through our collaboration we will also",
        "start": 1728.519,
        "duration": 5.61
    },
    {
        "text": "characterize and propose a new target",
        "start": 1732.09,
        "duration": 5.28
    },
    {
        "text": "and drug mechanisms of action and",
        "start": 1734.129,
        "duration": 7.351
    },
    {
        "text": "resistance for each of the dass's and I",
        "start": 1737.37,
        "duration": 5.97
    },
    {
        "text": "think most importantly and why it's",
        "start": 1741.48,
        "duration": 3.539
    },
    {
        "text": "important I think for the members of my",
        "start": 1743.34,
        "duration": 3.86
    },
    {
        "text": "group and also when you're considering",
        "start": 1745.019,
        "duration": 4.231
    },
    {
        "text": "what you're going to do in the future",
        "start": 1747.2,
        "duration": 5.26
    },
    {
        "text": "after you finish this program is the",
        "start": 1749.25,
        "duration": 6.029
    },
    {
        "text": "biological context around a lot of the",
        "start": 1752.46,
        "duration": 4.11
    },
    {
        "text": "work that we do so it's not just",
        "start": 1755.279,
        "duration": 4.441
    },
    {
        "text": "generating tables of genes or the most",
        "start": 1756.57,
        "duration": 4.859
    },
    {
        "text": "significant pathway that seems to be",
        "start": 1759.72,
        "duration": 3.72
    },
    {
        "text": "enriched it's actually taking that and",
        "start": 1761.429,
        "duration": 3.84
    },
    {
        "text": "boiling it down to something that you",
        "start": 1763.44,
        "duration": 3.42
    },
    {
        "text": "can speak with the clinician about so",
        "start": 1765.269,
        "duration": 3.811
    },
    {
        "text": "what is it specifically biologically",
        "start": 1766.86,
        "duration": 4.379
    },
    {
        "text": "that all of this data actually means and",
        "start": 1769.08,
        "duration": 3.599
    },
    {
        "text": "so that's why I think it's very",
        "start": 1771.239,
        "duration": 2.971
    },
    {
        "text": "important that if you don't have that",
        "start": 1772.679,
        "duration": 3.21
    },
    {
        "text": "sort of hybrid background that you",
        "start": 1774.21,
        "duration": 3.959
    },
    {
        "text": "really do seek that out it's not just",
        "start": 1775.889,
        "duration": 4.5
    },
    {
        "text": "about programming it's not just about",
        "start": 1778.169,
        "duration": 3.931
    },
    {
        "text": "understanding the biology actually the",
        "start": 1780.389,
        "duration": 3.75
    },
    {
        "text": "hybrid of the two makes you you know",
        "start": 1782.1,
        "duration": 7.289
    },
    {
        "text": "very valuable to the fauna in addition",
        "start": 1784.139,
        "duration": 7.471
    },
    {
        "text": "to that we we also license and build",
        "start": 1789.389,
        "duration": 4.5
    },
    {
        "text": "computational infrastructure and this is",
        "start": 1791.61,
        "duration": 4.11
    },
    {
        "text": "a necessary component I think of a lot",
        "start": 1793.889,
        "duration": 4.591
    },
    {
        "text": "of the work that we do many things you",
        "start": 1795.72,
        "duration": 5.13
    },
    {
        "text": "can't get off-the-shelf we've seen from",
        "start": 1798.48,
        "duration": 5.189
    },
    {
        "text": "academic groups and others oftentimes",
        "start": 1800.85,
        "duration": 4.409
    },
    {
        "text": "you're the ones that have to invent this",
        "start": 1803.669,
        "duration": 4.681
    },
    {
        "text": "this stuff and ultimately these things",
        "start": 1805.259,
        "duration": 5.01
    },
    {
        "text": "become commercialized and you know",
        "start": 1808.35,
        "duration": 4.019
    },
    {
        "text": "pharma companies and others end up",
        "start": 1810.269,
        "duration": 4.74
    },
    {
        "text": "licensing some of it but even then you",
        "start": 1812.369,
        "duration": 3.841
    },
    {
        "text": "know off-the-shelf products aren't",
        "start": 1815.009,
        "duration": 3.061
    },
    {
        "text": "aren't always available for the for the",
        "start": 1816.21,
        "duration": 6.419
    },
    {
        "text": "needs that you have so I just wanted to",
        "start": 1818.07,
        "duration": 8.39
    },
    {
        "text": "show this as as a diagram really to",
        "start": 1822.629,
        "duration": 6.39
    },
    {
        "text": "ground us you know about where",
        "start": 1826.46,
        "duration": 4.569
    },
    {
        "text": "computational biology fits into each one",
        "start": 1829.019,
        "duration": 4.98
    },
    {
        "text": "of these facets so we go so whether",
        "start": 1831.029,
        "duration": 5.12
    },
    {
        "text": "you're in academia or or in industry",
        "start": 1833.999,
        "duration": 4.92
    },
    {
        "text": "this same methodology applies where you",
        "start": 1836.149,
        "duration": 4.951
    },
    {
        "text": "start with the hypothesis you generated",
        "start": 1838.919,
        "duration": 4.801
    },
    {
        "text": "from that hypothesis you set up a study",
        "start": 1841.1,
        "duration": 6.149
    },
    {
        "text": "that study generates data produces some",
        "start": 1843.72,
        "duration": 5.85
    },
    {
        "text": "analysis that you would work on and then",
        "start": 1847.249,
        "duration": 5.01
    },
    {
        "text": "hopefully would generate even additional",
        "start": 1849.57,
        "duration": 6.089
    },
    {
        "text": "hypotheses beyond that and for us we",
        "start": 1852.259,
        "duration": 6.61
    },
    {
        "text": "would diverge onto the or we would split",
        "start": 1855.659,
        "duration": 6.24
    },
    {
        "text": "off and hopefully generate a drug and a",
        "start": 1858.869,
        "duration": 6.9
    },
    {
        "text": "diagnostic to go with it so where we fit",
        "start": 1861.899,
        "duration": 6.0
    },
    {
        "text": "in with each one of these is around",
        "start": 1865.769,
        "duration": 5.311
    },
    {
        "text": "hypothesis generation this is very",
        "start": 1867.899,
        "duration": 5.49
    },
    {
        "text": "important I think to take public data or",
        "start": 1871.08,
        "duration": 4.169
    },
    {
        "text": "our internal data and really help our",
        "start": 1873.389,
        "duration": 3.15
    },
    {
        "text": "scientists understand what that data",
        "start": 1875.249,
        "duration": 4.68
    },
    {
        "text": "mean and this includes both preclinical",
        "start": 1876.539,
        "duration": 5.85
    },
    {
        "text": "and clinical data evaluation and also",
        "start": 1879.929,
        "duration": 4.141
    },
    {
        "text": "from the discovery perspective can we",
        "start": 1882.389,
        "duration": 3.24
    },
    {
        "text": "identify new targets that we should be",
        "start": 1884.07,
        "duration": 3.929
    },
    {
        "text": "going after so it's not just target",
        "start": 1885.629,
        "duration": 3.99
    },
    {
        "text": "identification but also validation of",
        "start": 1887.999,
        "duration": 4.64
    },
    {
        "text": "targets that they may bring",
        "start": 1889.619,
        "duration": 3.02
    },
    {
        "text": "from there also setting up the studies",
        "start": 1892.68,
        "duration": 5.25
    },
    {
        "text": "themselves so what makes a good study",
        "start": 1895.86,
        "duration": 5.46
    },
    {
        "text": "helping our scientists understand how to",
        "start": 1897.93,
        "duration": 6.81
    },
    {
        "text": "sufficiently power the study and this",
        "start": 1901.32,
        "duration": 5.01
    },
    {
        "text": "goes for both preclinical and the",
        "start": 1904.74,
        "duration": 3.09
    },
    {
        "text": "clinical biomarkers studies that were",
        "start": 1906.33,
        "duration": 4.29
    },
    {
        "text": "involved with we also have a clinical",
        "start": 1907.83,
        "duration": 4.65
    },
    {
        "text": "bio stats group that does a lot of the",
        "start": 1910.62,
        "duration": 3.36
    },
    {
        "text": "main clinical study work but we're",
        "start": 1912.48,
        "duration": 4.1
    },
    {
        "text": "responsible for a lot of the biomarker",
        "start": 1913.98,
        "duration": 6.66
    },
    {
        "text": "design and then also generating a",
        "start": 1916.58,
        "duration": 5.86
    },
    {
        "text": "physical analysis plant that lay out",
        "start": 1920.64,
        "duration": 3.51
    },
    {
        "text": "very clearly what it is that we're going",
        "start": 1922.44,
        "duration": 3.47
    },
    {
        "text": "to do with the data when it comes back",
        "start": 1924.15,
        "duration": 4.77
    },
    {
        "text": "on the data side we were involved with",
        "start": 1925.91,
        "duration": 5.47
    },
    {
        "text": "data management you see in the data data",
        "start": 1928.92,
        "duration": 4.8
    },
    {
        "text": "visualization as I mentioned",
        "start": 1931.38,
        "duration": 4.86
    },
    {
        "text": "infrastructure development and then",
        "start": 1933.72,
        "duration": 4.08
    },
    {
        "text": "finally from the analysis side and this",
        "start": 1936.24,
        "duration": 2.82
    },
    {
        "text": "is really the bread and butter of what",
        "start": 1937.8,
        "duration": 4.05
    },
    {
        "text": "we do the statistical analysis data",
        "start": 1939.06,
        "duration": 5.39
    },
    {
        "text": "processing analysis pipeline development",
        "start": 1941.85,
        "duration": 4.44
    },
    {
        "text": "probably a lot of the things that people",
        "start": 1944.45,
        "duration": 4.66
    },
    {
        "text": "in this room do and also developing",
        "start": 1946.29,
        "duration": 8.37
    },
    {
        "text": "tools and algorithms so I won't belabor",
        "start": 1949.11,
        "duration": 6.78
    },
    {
        "text": "this because I think everyone in the",
        "start": 1954.66,
        "duration": 3.21
    },
    {
        "text": "room probably has some experience doing",
        "start": 1955.89,
        "duration": 3.57
    },
    {
        "text": "these things but it did want to show",
        "start": 1957.87,
        "duration": 3.9
    },
    {
        "text": "again you know where these things fit in",
        "start": 1959.46,
        "duration": 4.89
    },
    {
        "text": "so everything from hypothesis testing",
        "start": 1961.77,
        "duration": 4.98
    },
    {
        "text": "where you really do need it very clear",
        "start": 1964.35,
        "duration": 4.62
    },
    {
        "text": "and good grounding and statistics",
        "start": 1966.75,
        "duration": 4.32
    },
    {
        "text": "through machine learning where you're",
        "start": 1968.97,
        "duration": 3.6
    },
    {
        "text": "doing classification and you're trying",
        "start": 1971.07,
        "duration": 3.6
    },
    {
        "text": "to build models that predict something",
        "start": 1972.57,
        "duration": 3.75
    },
    {
        "text": "so in this case we could be trying to",
        "start": 1974.67,
        "duration": 4.53
    },
    {
        "text": "predict outcome or predict resistant who",
        "start": 1976.32,
        "duration": 5.91
    },
    {
        "text": "are drug and then also very importantly",
        "start": 1979.2,
        "duration": 5.49
    },
    {
        "text": "data mining and visualization this is",
        "start": 1982.23,
        "duration": 4.22
    },
    {
        "text": "very key to help our scientists",
        "start": 1984.69,
        "duration": 3.48
    },
    {
        "text": "translate this is something that's",
        "start": 1986.45,
        "duration": 3.82
    },
    {
        "text": "interpreted will by clinicians and",
        "start": 1988.17,
        "duration": 4.62
    },
    {
        "text": "others that may be in the death but",
        "start": 1990.27,
        "duration": 4.02
    },
    {
        "text": "ultimately all of these different",
        "start": 1992.79,
        "duration": 4.32
    },
    {
        "text": "analyses again feed into another",
        "start": 1994.29,
        "duration": 5.28
    },
    {
        "text": "analysis that includes trying to",
        "start": 1997.11,
        "duration": 4.11
    },
    {
        "text": "understand the biological context so",
        "start": 1999.57,
        "duration": 3.57
    },
    {
        "text": "what does it all mean this could include",
        "start": 2001.22,
        "duration": 4.26
    },
    {
        "text": "pathway and network analyses or",
        "start": 2003.14,
        "duration": 4.17
    },
    {
        "text": "functional annotations or other other",
        "start": 2005.48,
        "duration": 5.64
    },
    {
        "text": "approaches one that some of the partner",
        "start": 2007.31,
        "duration": 5.91
    },
    {
        "text": "we have as I mentioned clinical stats",
        "start": 2011.12,
        "duration": 4.77
    },
    {
        "text": "non clinical stats we have a research",
        "start": 2013.22,
        "duration": 5.19
    },
    {
        "text": "and development IT group that's specific",
        "start": 2015.89,
        "duration": 6.419
    },
    {
        "text": "for us they help get a set up on things",
        "start": 2018.41,
        "duration": 5.37
    },
    {
        "text": "like the cloud and and other",
        "start": 2022.309,
        "duration": 3.841
    },
    {
        "text": "infrastructure related things we have a",
        "start": 2023.78,
        "duration": 4.26
    },
    {
        "text": "discovery scientist group that spans all",
        "start": 2026.15,
        "duration": 4.38
    },
    {
        "text": "the therapeutic areas and that discovery",
        "start": 2028.04,
        "duration": 4.08
    },
    {
        "text": "scientist group is responsible for",
        "start": 2030.53,
        "duration": 4.89
    },
    {
        "text": "answering the bigger question so what",
        "start": 2032.12,
        "duration": 5.28
    },
    {
        "text": "could apply to both immunology and",
        "start": 2035.42,
        "duration": 4.71
    },
    {
        "text": "college how can they help us design",
        "start": 2037.4,
        "duration": 5.55
    },
    {
        "text": "studies around understanding diseases",
        "start": 2040.13,
        "duration": 4.62
    },
    {
        "text": "that may span both or infrastructure",
        "start": 2042.95,
        "duration": 5.55
    },
    {
        "text": "that would actually benefit both and",
        "start": 2044.75,
        "duration": 5.55
    },
    {
        "text": "then obviously we rely heavily on",
        "start": 2048.5,
        "duration": 4.83
    },
    {
        "text": "external vendors and then also partners",
        "start": 2050.3,
        "duration": 5.099
    },
    {
        "text": "within other therapeutic areas of the",
        "start": 2053.33,
        "duration": 6.839
    },
    {
        "text": "immunology maritime so to quickly jump",
        "start": 2055.399,
        "duration": 6.571
    },
    {
        "text": "into some of the projects that we deal",
        "start": 2060.169,
        "duration": 4.26
    },
    {
        "text": "with across the different data so this",
        "start": 2061.97,
        "duration": 5.37
    },
    {
        "text": "is the Hien - the overarching picture of",
        "start": 2064.429,
        "duration": 6.271
    },
    {
        "text": "what it is that the focus really is as",
        "start": 2067.34,
        "duration": 5.4
    },
    {
        "text": "Nick mentioned we really want to hone in",
        "start": 2070.7,
        "duration": 4.11
    },
    {
        "text": "on the big diseases and in this case",
        "start": 2072.74,
        "duration": 4.77
    },
    {
        "text": "because he represents a large number of",
        "start": 2074.81,
        "duration": 4.859
    },
    {
        "text": "diseases we've really tried to focus on",
        "start": 2077.51,
        "duration": 5.55
    },
    {
        "text": "specific diseases so AML mdf he starts",
        "start": 2079.669,
        "duration": 6.0
    },
    {
        "text": "b-cell lymphoma at multiple myeloma and",
        "start": 2083.06,
        "duration": 4.65
    },
    {
        "text": "also other b-cell malignancies that can",
        "start": 2085.669,
        "duration": 6.201
    },
    {
        "text": "be targeted with drugs like that period",
        "start": 2087.71,
        "duration": 4.16
    },
    {
        "text": "and just to show how all these diseases",
        "start": 2092.29,
        "duration": 4.96
    },
    {
        "text": "are related",
        "start": 2095.51,
        "duration": 4.26
    },
    {
        "text": "if this isn't familiar to everyone in",
        "start": 2097.25,
        "duration": 4.79
    },
    {
        "text": "the room I'll just quickly walk through",
        "start": 2099.77,
        "duration": 6.32
    },
    {
        "text": "so this shows b cell development and",
        "start": 2102.04,
        "duration": 7.33
    },
    {
        "text": "where specific mutation can occur in",
        "start": 2106.09,
        "duration": 6.55
    },
    {
        "text": "these B cells and as they travel or as",
        "start": 2109.37,
        "duration": 7.17
    },
    {
        "text": "they mature and where specific mutations",
        "start": 2112.64,
        "duration": 6.99
    },
    {
        "text": "can lead to different diseases so CLL",
        "start": 2116.54,
        "duration": 6.08
    },
    {
        "text": "the mantle cell follicular lymphoma",
        "start": 2119.63,
        "duration": 4.98
    },
    {
        "text": "Burkitt's lymphoma and Hodgkin's",
        "start": 2122.62,
        "duration": 6.19
    },
    {
        "text": "lymphoma and then DLBCL over here",
        "start": 2124.61,
        "duration": 5.6
    },
    {
        "text": "and why this is important of",
        "start": 2128.81,
        "duration": 2.91
    },
    {
        "text": "understanding this progression",
        "start": 2130.21,
        "duration": 4.24
    },
    {
        "text": "understanding some of the mutations that",
        "start": 2131.72,
        "duration": 5.1
    },
    {
        "text": "occur can help us develop better drug",
        "start": 2134.45,
        "duration": 7.86
    },
    {
        "text": "and in this case if we look at the",
        "start": 2136.82,
        "duration": 7.26
    },
    {
        "text": "specific protein called BTK that Nick",
        "start": 2142.31,
        "duration": 5.04
    },
    {
        "text": "mentioned tyrosine kinase this is",
        "start": 2144.08,
        "duration": 4.98
    },
    {
        "text": "actually this actually plays a part in",
        "start": 2147.35,
        "duration": 6.12
    },
    {
        "text": "in this entire B cell maturation and by",
        "start": 2149.06,
        "duration": 7.38
    },
    {
        "text": "blocking it you can actually impact many",
        "start": 2153.47,
        "duration": 8.25
    },
    {
        "text": "of these diseases very well and so what",
        "start": 2156.44,
        "duration": 6.54
    },
    {
        "text": "we've done with I've written it is",
        "start": 2161.72,
        "duration": 3.33
    },
    {
        "text": "specifically targeted and a lot of the",
        "start": 2162.98,
        "duration": 3.54
    },
    {
        "text": "results were seen in these clinical",
        "start": 2165.05,
        "duration": 2.91
    },
    {
        "text": "studies has been very positive and",
        "start": 2166.52,
        "duration": 5.28
    },
    {
        "text": "encouraging so this actually has led to",
        "start": 2167.96,
        "duration": 5.55
    },
    {
        "text": "I burned its breakthrough status for",
        "start": 2171.8,
        "duration": 5.78
    },
    {
        "text": "anthem cell lymphoma and CLL and",
        "start": 2173.51,
        "duration": 7.74
    },
    {
        "text": "hopefully we see as good results in some",
        "start": 2177.58,
        "duration": 4.84
    },
    {
        "text": "of the future studies were dealing with",
        "start": 2181.25,
        "duration": 5.84
    },
    {
        "text": "so for mantle cell lymphoma specifically",
        "start": 2182.42,
        "duration": 7.05
    },
    {
        "text": "its shown impressive results and this",
        "start": 2187.09,
        "duration": 4.6
    },
    {
        "text": "actually would lead to the breakthrough",
        "start": 2189.47,
        "duration": 6.24
    },
    {
        "text": "status but I think one important thing",
        "start": 2191.69,
        "duration": 5.7
    },
    {
        "text": "here is something that the computational",
        "start": 2195.71,
        "duration": 3.45
    },
    {
        "text": "biology can bring to the table and",
        "start": 2197.39,
        "duration": 3.3
    },
    {
        "text": "that's really trying to understand the",
        "start": 2199.16,
        "duration": 3.15
    },
    {
        "text": "biology of its activity and the",
        "start": 2200.69,
        "duration": 4.64
    },
    {
        "text": "potential mechanisms of resistance so",
        "start": 2202.31,
        "duration": 6.6
    },
    {
        "text": "not every patient is going to benefit so",
        "start": 2205.33,
        "duration": 5.65
    },
    {
        "text": "understanding why those patients don't",
        "start": 2208.91,
        "duration": 4.67
    },
    {
        "text": "benefit it's very important for us to",
        "start": 2210.98,
        "duration": 5.19
    },
    {
        "text": "consider combination therapies or also",
        "start": 2213.58,
        "duration": 7.93
    },
    {
        "text": "lead onto the next drug I'll skip over",
        "start": 2216.17,
        "duration": 7.62
    },
    {
        "text": "this for the sake of time so just to",
        "start": 2221.51,
        "duration": 4.59
    },
    {
        "text": "mention the studies the mantle cell",
        "start": 2223.79,
        "duration": 5.96
    },
    {
        "text": "lymphoma study for this is M field 2001",
        "start": 2226.1,
        "duration": 7.14
    },
    {
        "text": "Arkadiy this was a single agent for",
        "start": 2229.75,
        "duration": 4.3
    },
    {
        "text": "ibrutinib",
        "start": 2233.24,
        "duration": 6.39
    },
    {
        "text": "at 550 milligram subjects with mantle",
        "start": 2234.05,
        "duration": 7.8
    },
    {
        "text": "cell lymphoma had to repeat one to five",
        "start": 2239.63,
        "duration": 5.13
    },
    {
        "text": "prior lines of therapy previously",
        "start": 2241.85,
        "duration": 5.19
    },
    {
        "text": "treated with the rituximab or Velcade",
        "start": 2244.76,
        "duration": 7.31
    },
    {
        "text": "and the primary endpoint in this case is",
        "start": 2247.04,
        "duration": 8.91
    },
    {
        "text": "objective response rate so for those not",
        "start": 2252.07,
        "duration": 5.68
    },
    {
        "text": "familiar this is looking at those",
        "start": 2255.95,
        "duration": 3.81
    },
    {
        "text": "complete responders and those partial",
        "start": 2257.75,
        "duration": 5.3
    },
    {
        "text": "responders to ibrutinib",
        "start": 2259.76,
        "duration": 4.85
    },
    {
        "text": "didn't have their their disease",
        "start": 2263.05,
        "duration": 4.5
    },
    {
        "text": "completely eradicated to those that had",
        "start": 2264.61,
        "duration": 5.94
    },
    {
        "text": "some showed some tumor regression this",
        "start": 2267.55,
        "duration": 6.96
    },
    {
        "text": "is what factored in the overall rate so",
        "start": 2270.55,
        "duration": 5.58
    },
    {
        "text": "in this study we saw a sixty two point",
        "start": 2274.51,
        "duration": 3.63
    },
    {
        "text": "seven percent overall response rate so",
        "start": 2276.13,
        "duration": 4.2
    },
    {
        "text": "very good but not every patient",
        "start": 2278.14,
        "duration": 5.19
    },
    {
        "text": "responded and so what we did in the",
        "start": 2280.33,
        "duration": 5.01
    },
    {
        "text": "translational group is then asked of the",
        "start": 2283.33,
        "duration": 3.96
    },
    {
        "text": "patients that didn't respond there were",
        "start": 2285.34,
        "duration": 3.84
    },
    {
        "text": "twenty five who seemed to have",
        "start": 2287.29,
        "duration": 4.08
    },
    {
        "text": "progressive disease after the first",
        "start": 2289.18,
        "duration": 6.6
    },
    {
        "text": "evaluation and of those twenty three had",
        "start": 2291.37,
        "duration": 6.48
    },
    {
        "text": "DNA that we could extract successfully",
        "start": 2295.78,
        "duration": 4.89
    },
    {
        "text": "from their sample and so from there what",
        "start": 2297.85,
        "duration": 5.31
    },
    {
        "text": "we've done is a targeted panel of ninety",
        "start": 2300.67,
        "duration": 5.72
    },
    {
        "text": "seven genes that are specifically around",
        "start": 2303.16,
        "duration": 7.08
    },
    {
        "text": "the BCR pathway BTK and some other",
        "start": 2306.39,
        "duration": 6.34
    },
    {
        "text": "related pathways that we think would",
        "start": 2310.24,
        "duration": 4.86
    },
    {
        "text": "generate some primary resistance to",
        "start": 2312.73,
        "duration": 4.68
    },
    {
        "text": "ibrutinib and so we've done a deep",
        "start": 2315.1,
        "duration": 5.13
    },
    {
        "text": "sequencing of those two about a thousand",
        "start": 2317.41,
        "duration": 4.98
    },
    {
        "text": "acts and in addition to that has done an",
        "start": 2320.23,
        "duration": 5.58
    },
    {
        "text": "excellent example so i can't show you",
        "start": 2322.39,
        "duration": 5.19
    },
    {
        "text": "all the results from this but i think",
        "start": 2325.81,
        "duration": 3.84
    },
    {
        "text": "some of the results were encouraging and",
        "start": 2327.58,
        "duration": 4.68
    },
    {
        "text": "think we have some interesting targets",
        "start": 2329.65,
        "duration": 4.71
    },
    {
        "text": "to follow up on but there's a lot more",
        "start": 2332.26,
        "duration": 3.63
    },
    {
        "text": "work there and obviously if you've done",
        "start": 2334.36,
        "duration": 3.21
    },
    {
        "text": "this type of computational work before",
        "start": 2335.89,
        "duration": 3.75
    },
    {
        "text": "you know there are many different ways",
        "start": 2337.57,
        "duration": 4.47
    },
    {
        "text": "life in days next-generation sequencing",
        "start": 2339.64,
        "duration": 4.77
    },
    {
        "text": "data many different methodologies can be",
        "start": 2342.04,
        "duration": 4.08
    },
    {
        "text": "applied to it and betting this",
        "start": 2344.41,
        "duration": 7.95
    },
    {
        "text": "methodology is on the multiple myeloma",
        "start": 2346.12,
        "duration": 9.71
    },
    {
        "text": "side Dara tuam ab Nick mentioned and",
        "start": 2352.36,
        "duration": 6.15
    },
    {
        "text": "this this is about ten to fifteen",
        "start": 2355.83,
        "duration": 6.54
    },
    {
        "text": "percent of all hematological cancers",
        "start": 2358.51,
        "duration": 6.54
    },
    {
        "text": "it's most prevalent it's the most",
        "start": 2362.37,
        "duration": 4.48
    },
    {
        "text": "prevalent knee malignancy in people over",
        "start": 2365.05,
        "duration": 6.12
    },
    {
        "text": "65 years old and really there's there's",
        "start": 2366.85,
        "duration": 6.51
    },
    {
        "text": "a huge need I think that it's a huge",
        "start": 2371.17,
        "duration": 3.45
    },
    {
        "text": "market and their potential for newer",
        "start": 2373.36,
        "duration": 3.12
    },
    {
        "text": "drugs with new mechanisms of action that",
        "start": 2374.62,
        "duration": 6.21
    },
    {
        "text": "are certainly there so one drug Derek",
        "start": 2376.48,
        "duration": 5.97
    },
    {
        "text": "whom AB is one that we've been taking",
        "start": 2380.83,
        "duration": 3.9
    },
    {
        "text": "through the clinic and again this",
        "start": 2382.45,
        "duration": 4.02
    },
    {
        "text": "received breakthrough status multiple",
        "start": 2384.73,
        "duration": 5.22
    },
    {
        "text": "myeloma treatment it targets cd38 this",
        "start": 2386.47,
        "duration": 5.4
    },
    {
        "text": "is highly expressed on multiple myeloma",
        "start": 2389.95,
        "duration": 5.61
    },
    {
        "text": "cells and other he malignancies",
        "start": 2391.87,
        "duration": 5.72
    },
    {
        "text": "interestingly it has multiple mecca's",
        "start": 2395.56,
        "duration": 5.19
    },
    {
        "text": "mechanisms of action so everything from",
        "start": 2397.59,
        "duration": 9.91
    },
    {
        "text": "CDC ADCC a DCP an MVS see our mechanisms",
        "start": 2400.75,
        "duration": 9.51
    },
    {
        "text": "that there are two Matt could be using",
        "start": 2407.5,
        "duration": 4.92
    },
    {
        "text": "so one thing that we need to do and",
        "start": 2410.26,
        "duration": 3.6
    },
    {
        "text": "really understand is tease out the",
        "start": 2412.42,
        "duration": 3.56
    },
    {
        "text": "specific mechanisms of action that are",
        "start": 2413.86,
        "duration": 6.26
    },
    {
        "text": "occurring in the patients that respond",
        "start": 2415.98,
        "duration": 6.85
    },
    {
        "text": "so the key translational objectives for",
        "start": 2420.12,
        "duration": 4.57
    },
    {
        "text": "this program are really contribute to",
        "start": 2422.83,
        "duration": 4.38
    },
    {
        "text": "the DOE selection and then from our",
        "start": 2424.69,
        "duration": 4.23
    },
    {
        "text": "perspective in translational research to",
        "start": 2427.21,
        "duration": 3.96
    },
    {
        "text": "explore the biomarkers that are",
        "start": 2428.92,
        "duration": 4.32
    },
    {
        "text": "predictive of response and ultimately",
        "start": 2431.17,
        "duration": 4.76
    },
    {
        "text": "lead to a development of a co diagnostic",
        "start": 2433.24,
        "duration": 5.49
    },
    {
        "text": "and then there are a couple others that",
        "start": 2435.93,
        "duration": 4.75
    },
    {
        "text": "that don't necessarily involve the",
        "start": 2438.73,
        "duration": 6.14
    },
    {
        "text": "computational group but are listed here",
        "start": 2440.68,
        "duration": 4.19
    },
    {
        "text": "okay so what are we doing bioinformatic",
        "start": 2445.86,
        "duration": 5.14
    },
    {
        "text": "lis so one of the powerful things about",
        "start": 2448.27,
        "duration": 4.62
    },
    {
        "text": "running multiple studies with the same",
        "start": 2451.0,
        "duration": 4.23
    },
    {
        "text": "drug in disease populations that are",
        "start": 2452.89,
        "duration": 4.08
    },
    {
        "text": "similar and maybe not identical but",
        "start": 2455.23,
        "duration": 2.97
    },
    {
        "text": "similar is that you can now start",
        "start": 2456.97,
        "duration": 4.65
    },
    {
        "text": "looking at cross studies so here we have",
        "start": 2458.2,
        "duration": 6.45
    },
    {
        "text": "for multiple myeloma studies that we",
        "start": 2461.62,
        "duration": 5.67
    },
    {
        "text": "have ongoing where data is now coming in",
        "start": 2464.65,
        "duration": 5.22
    },
    {
        "text": "or have already had their databases",
        "start": 2467.29,
        "duration": 5.4
    },
    {
        "text": "close down that we can start mining",
        "start": 2469.87,
        "duration": 3.96
    },
    {
        "text": "through this data and get a better",
        "start": 2472.69,
        "duration": 3.33
    },
    {
        "text": "understanding of what it is that really",
        "start": 2473.83,
        "duration": 5.79
    },
    {
        "text": "is the mechanism in play here so some of",
        "start": 2476.02,
        "duration": 5.72
    },
    {
        "text": "the things that we're measuring is",
        "start": 2479.62,
        "duration": 4.74
    },
    {
        "text": "looking at the mechanism of action a DCC",
        "start": 2481.74,
        "duration": 5.86
    },
    {
        "text": "and PDC and response mechanisms the",
        "start": 2484.36,
        "duration": 6.63
    },
    {
        "text": "biomarkers measured include cell levels",
        "start": 2487.6,
        "duration": 6.06
    },
    {
        "text": "and you know typing in DBM C's and bone",
        "start": 2490.99,
        "duration": 6.03
    },
    {
        "text": "now so looking at and K cell activated",
        "start": 2493.66,
        "duration": 7.23
    },
    {
        "text": "in Kaysville T cell cd38 expression",
        "start": 2497.02,
        "duration": 9.05
    },
    {
        "text": "itself complement inhibitory proteins",
        "start": 2500.89,
        "duration": 8.25
    },
    {
        "text": "and then also looking at exploratory",
        "start": 2506.07,
        "duration": 6.49
    },
    {
        "text": "proteomic panel this is looking at soma",
        "start": 2509.14,
        "duration": 5.94
    },
    {
        "text": "logic panels or you can measure in serum",
        "start": 2512.56,
        "duration": 5.82
    },
    {
        "text": "you know up to a thousand protein and",
        "start": 2515.08,
        "duration": 4.59
    },
    {
        "text": "then in addition to that looking at",
        "start": 2518.38,
        "duration": 4.29
    },
    {
        "text": "snips and copy number variation in DBM",
        "start": 2519.67,
        "duration": 4.38
    },
    {
        "text": "see",
        "start": 2522.67,
        "duration": 2.79
    },
    {
        "text": "so taken together I think this is very",
        "start": 2524.05,
        "duration": 3.57
    },
    {
        "text": "interesting and powerful way to maybe",
        "start": 2525.46,
        "duration": 3.6
    },
    {
        "text": "glean some information from these",
        "start": 2527.62,
        "duration": 3.21
    },
    {
        "text": "studies that have captured data and",
        "start": 2529.06,
        "duration": 5.42
    },
    {
        "text": "consistent way across multiple studies",
        "start": 2530.83,
        "duration": 5.67
    },
    {
        "text": "another important thing is minimal",
        "start": 2534.48,
        "duration": 4.06
    },
    {
        "text": "residual disease and this applies not",
        "start": 2536.5,
        "duration": 4.47
    },
    {
        "text": "just to multiple myeloma but also AML",
        "start": 2538.54,
        "duration": 4.92
    },
    {
        "text": "and others and the idea is that if we",
        "start": 2540.97,
        "duration": 5.49
    },
    {
        "text": "don't know we don't really know if the",
        "start": 2543.46,
        "duration": 6.75
    },
    {
        "text": "patients cured just by some test right",
        "start": 2546.46,
        "duration": 7.29
    },
    {
        "text": "so this diagram at the bottom shows a",
        "start": 2550.21,
        "duration": 5.15
    },
    {
        "text": "patient that may be driven into",
        "start": 2553.75,
        "duration": 4.77
    },
    {
        "text": "cytological remission and then further",
        "start": 2555.36,
        "duration": 6.04
    },
    {
        "text": "into CR and this this would be minimal",
        "start": 2558.52,
        "duration": 5.91
    },
    {
        "text": "residual disease positive in other words",
        "start": 2561.4,
        "duration": 5.28
    },
    {
        "text": "they still have some minimal residual",
        "start": 2564.43,
        "duration": 5.04
    },
    {
        "text": "disease and what is it that we can do",
        "start": 2566.68,
        "duration": 4.56
    },
    {
        "text": "with daric pugh in lab and other drugs",
        "start": 2569.47,
        "duration": 4.11
    },
    {
        "text": "to drive them even further to a deeper",
        "start": 2571.24,
        "duration": 6.27
    },
    {
        "text": "clinical response so one obvious problem",
        "start": 2573.58,
        "duration": 6.27
    },
    {
        "text": "with this is that there's we lack a",
        "start": 2577.51,
        "duration": 5.25
    },
    {
        "text": "current standard for measuring what MRD",
        "start": 2579.85,
        "duration": 6.03
    },
    {
        "text": "actually is and so in this case there",
        "start": 2582.76,
        "duration": 4.86
    },
    {
        "text": "are three different assays listed here",
        "start": 2585.88,
        "duration": 5.16
    },
    {
        "text": "there are other but among these assays",
        "start": 2587.62,
        "duration": 5.04
    },
    {
        "text": "which is the best which is the most",
        "start": 2591.04,
        "duration": 3.3
    },
    {
        "text": "sensitive which is the most reliable and",
        "start": 2592.66,
        "duration": 2.91
    },
    {
        "text": "this is something that's very important",
        "start": 2594.34,
        "duration": 2.91
    },
    {
        "text": "for us to figure out as a community not",
        "start": 2595.57,
        "duration": 5.48
    },
    {
        "text": "just J&J because those patients that",
        "start": 2597.25,
        "duration": 7.71
    },
    {
        "text": "achieve this very deep remission may in",
        "start": 2601.05,
        "duration": 5.47
    },
    {
        "text": "fact go on to generate these long",
        "start": 2604.96,
        "duration": 4.91
    },
    {
        "text": "survival pill but you may also have",
        "start": 2606.52,
        "duration": 5.79
    },
    {
        "text": "monitoring of these patients well over",
        "start": 2609.87,
        "duration": 5.05
    },
    {
        "text": "time so after they are driven into",
        "start": 2612.31,
        "duration": 4.74
    },
    {
        "text": "remission periodic sampling of these",
        "start": 2614.92,
        "duration": 4.77
    },
    {
        "text": "patient using the most sensitive assay",
        "start": 2617.05,
        "duration": 5.16
    },
    {
        "text": "and most reliable acids get your hands",
        "start": 2619.69,
        "duration": 5.19
    },
    {
        "text": "on is important to see those patients",
        "start": 2622.21,
        "duration": 4.26
    },
    {
        "text": "that would have this pump that occurs",
        "start": 2624.88,
        "duration": 4.44
    },
    {
        "text": "later so you can then treat them with",
        "start": 2626.47,
        "duration": 5.18
    },
    {
        "text": "either the same drug or some other drug",
        "start": 2629.32,
        "duration": 5.57
    },
    {
        "text": "before they actually have a full return",
        "start": 2631.65,
        "duration": 6.43
    },
    {
        "text": "so early detection of this recurrence is",
        "start": 2634.89,
        "duration": 7.57
    },
    {
        "text": "very important so across all the studies",
        "start": 2638.08,
        "duration": 5.85
    },
    {
        "text": "and I think this doesn't just apply to",
        "start": 2642.46,
        "duration": 5.67
    },
    {
        "text": "multiple myeloma but understanding creme",
        "start": 2643.93,
        "duration": 8.49
    },
    {
        "text": "malignancy or you know clinically",
        "start": 2648.13,
        "duration": 6.81
    },
    {
        "text": "indolent disease and its progression",
        "start": 2652.42,
        "duration": 3.42
    },
    {
        "text": "into",
        "start": 2654.94,
        "duration": 3.63
    },
    {
        "text": "into a more aggressive disease and a",
        "start": 2655.84,
        "duration": 4.019
    },
    {
        "text": "disease it's very hard to treat if",
        "start": 2658.57,
        "duration": 2.64
    },
    {
        "text": "something that's very important to it as",
        "start": 2659.859,
        "duration": 3.451
    },
    {
        "text": "well so if we look at the disease",
        "start": 2661.21,
        "duration": 3.96
    },
    {
        "text": "spectrum of multiple myeloma and this",
        "start": 2663.31,
        "duration": 3.96
    },
    {
        "text": "again could apply to AML and other",
        "start": 2665.17,
        "duration": 4.83
    },
    {
        "text": "diseases where you may start with this",
        "start": 2667.27,
        "duration": 4.829
    },
    {
        "text": "smoldering pre malignant state and",
        "start": 2670.0,
        "duration": 4.5
    },
    {
        "text": "ultimately get newly diagnosed multiple",
        "start": 2672.099,
        "duration": 5.101
    },
    {
        "text": "myeloma and then relapse and then",
        "start": 2674.5,
        "duration": 6.39
    },
    {
        "text": "relapse refractory disease if we capture",
        "start": 2677.2,
        "duration": 6.54
    },
    {
        "text": "DNA and RNA sequencing data tumor and an",
        "start": 2680.89,
        "duration": 5.4
    },
    {
        "text": "immune cell profiling and also Cori",
        "start": 2683.74,
        "duration": 3.96
    },
    {
        "text": "ohmic profiling we can start to",
        "start": 2686.29,
        "duration": 4.2
    },
    {
        "text": "understand and tease apart what what is",
        "start": 2687.7,
        "duration": 7.56
    },
    {
        "text": "actually happening what is what makes a",
        "start": 2690.49,
        "duration": 6.359
    },
    {
        "text": "patient high-risk can move from",
        "start": 2695.26,
        "duration": 4.2
    },
    {
        "text": "smoldering a smaller multiple myeloma",
        "start": 2696.849,
        "duration": 7.591
    },
    {
        "text": "state to and this is something that",
        "start": 2699.46,
        "duration": 7.29
    },
    {
        "text": "really can feed back into our daffy",
        "start": 2704.44,
        "duration": 5.85
    },
    {
        "text": "pipeline and help us you know with new",
        "start": 2706.75,
        "duration": 5.45
    },
    {
        "text": "targets for teeth out redirection",
        "start": 2710.29,
        "duration": 6.36
    },
    {
        "text": "chimeric antigen checkpoints and other",
        "start": 2712.2,
        "duration": 8.5
    },
    {
        "text": "targeted therapy so an interesting",
        "start": 2716.65,
        "duration": 5.61
    },
    {
        "text": "project that we're also involved with",
        "start": 2720.7,
        "duration": 4.35
    },
    {
        "text": "the team is a collaboration with the MMR",
        "start": 2722.26,
        "duration": 5.849
    },
    {
        "text": "app and the MMRF is the multiple myeloma",
        "start": 2725.05,
        "duration": 5.309
    },
    {
        "text": "Research Foundation this is an",
        "start": 2728.109,
        "duration": 4.441
    },
    {
        "text": "charitable organization founded by a",
        "start": 2730.359,
        "duration": 4.111
    },
    {
        "text": "patient actually they had multiple",
        "start": 2732.55,
        "duration": 5.76
    },
    {
        "text": "myeloma but she also was a Pharma",
        "start": 2734.47,
        "duration": 5.58
    },
    {
        "text": "executive and so she had a good",
        "start": 2738.31,
        "duration": 3.45
    },
    {
        "text": "understanding of what it takes to",
        "start": 2740.05,
        "duration": 4.41
    },
    {
        "text": "actually create new or develop new drugs",
        "start": 2741.76,
        "duration": 6.089
    },
    {
        "text": "to treat disease and she started this as",
        "start": 2744.46,
        "duration": 5.58
    },
    {
        "text": "a consortium of 16 leading academic",
        "start": 2747.849,
        "duration": 4.891
    },
    {
        "text": "centers and as part of this multiple",
        "start": 2750.04,
        "duration": 5.13
    },
    {
        "text": "myeloma Research Foundation is this",
        "start": 2752.74,
        "duration": 5.25
    },
    {
        "text": "commpass study and so this is a the goal",
        "start": 2755.17,
        "duration": 6.12
    },
    {
        "text": "is to profile and fully characterize the",
        "start": 2757.99,
        "duration": 5.19
    },
    {
        "text": "thousands multiple myeloma patients and",
        "start": 2761.29,
        "duration": 4.98
    },
    {
        "text": "and then follow them longitudinally for",
        "start": 2763.18,
        "duration": 5.28
    },
    {
        "text": "ten years so this is a massive amount of",
        "start": 2766.27,
        "duration": 4.5
    },
    {
        "text": "data being collected and a huge resource",
        "start": 2768.46,
        "duration": 5.28
    },
    {
        "text": "for the community that studying multiple",
        "start": 2770.77,
        "duration": 4.86
    },
    {
        "text": "myeloma and the goal of this is really",
        "start": 2773.74,
        "duration": 5.16
    },
    {
        "text": "to make all of this really available so",
        "start": 2775.63,
        "duration": 6.66
    },
    {
        "text": "J&J has been a sponsor of this and by",
        "start": 2778.9,
        "duration": 5.31
    },
    {
        "text": "paying into this we get six-month early",
        "start": 2782.29,
        "duration": 3.6
    },
    {
        "text": "access to the data but after that it",
        "start": 2784.21,
        "duration": 3.86
    },
    {
        "text": "becomes publicly available",
        "start": 2785.89,
        "duration": 5.15
    },
    {
        "text": "so everything from flow cytometry RNA",
        "start": 2788.07,
        "duration": 5.82
    },
    {
        "text": "seek hold vehicle exome and whole genome",
        "start": 2791.04,
        "duration": 5.97
    },
    {
        "text": "chromosome analysis and then also",
        "start": 2793.89,
        "duration": 5.22
    },
    {
        "text": "another contribution that JJ has made is",
        "start": 2797.01,
        "duration": 4.11
    },
    {
        "text": "looking at circulating multiple myeloma",
        "start": 2799.11,
        "duration": 4.23
    },
    {
        "text": "cells so this plays into the the work",
        "start": 2801.12,
        "duration": 5.07
    },
    {
        "text": "that Nick had presented with with the",
        "start": 2803.34,
        "duration": 5.69
    },
    {
        "text": "vertex platform",
        "start": 2806.19,
        "duration": 2.84
    },
    {
        "text": "so I think maybe I'll just comment here",
        "start": 2809.849,
        "duration": 5.5
    },
    {
        "text": "about the different standard of care",
        "start": 2813.25,
        "duration": 5.25
    },
    {
        "text": "agents being used so they generally fall",
        "start": 2815.349,
        "duration": 5.281
    },
    {
        "text": "into different classes though Korea film",
        "start": 2818.5,
        "duration": 4.32
    },
    {
        "text": "inhibitors alkylating agents and then",
        "start": 2820.63,
        "duration": 4.86
    },
    {
        "text": "image and it's up to the physician to",
        "start": 2822.82,
        "duration": 4.92
    },
    {
        "text": "treat these patients however they want",
        "start": 2825.49,
        "duration": 3.629
    },
    {
        "text": "so what's being tracked",
        "start": 2827.74,
        "duration": 3.72
    },
    {
        "text": "among these thousand patients is all the",
        "start": 2829.119,
        "duration": 3.811
    },
    {
        "text": "different treatments they receive so you",
        "start": 2831.46,
        "duration": 3.63
    },
    {
        "text": "can start easing that apart as well when",
        "start": 2832.93,
        "duration": 3.99
    },
    {
        "text": "you look at the clinical information and",
        "start": 2835.09,
        "duration": 5.24
    },
    {
        "text": "compared to some of the journal X data",
        "start": 2836.92,
        "duration": 3.41
    },
    {
        "text": "so this is a little dated at this point",
        "start": 2841.71,
        "duration": 6.85
    },
    {
        "text": "but as of last year there were a",
        "start": 2845.2,
        "duration": 4.89
    },
    {
        "text": "thousand patients that had been screened",
        "start": 2848.56,
        "duration": 7.309
    },
    {
        "text": "and 669 of them accruing early rapidly",
        "start": 2850.09,
        "duration": 8.4
    },
    {
        "text": "they're now far beyond that this year",
        "start": 2855.869,
        "duration": 4.961
    },
    {
        "text": "with the interim analysis seven data",
        "start": 2858.49,
        "duration": 4.859
    },
    {
        "text": "release but as of last year the good the",
        "start": 2860.83,
        "duration": 4.23
    },
    {
        "text": "interim analysis six and if you were to",
        "start": 2863.349,
        "duration": 3.061
    },
    {
        "text": "go on their website you should be able",
        "start": 2865.06,
        "duration": 4.17
    },
    {
        "text": "to see this data you'll see about 600",
        "start": 2866.41,
        "duration": 8.64
    },
    {
        "text": "patients are enrolled I'll skip over",
        "start": 2869.23,
        "duration": 9.389
    },
    {
        "text": "that just to give a quick idea of the",
        "start": 2875.05,
        "duration": 5.49
    },
    {
        "text": "type of data that is being generated",
        "start": 2878.619,
        "duration": 5.521
    },
    {
        "text": "here so this is survival plot broken out",
        "start": 2880.54,
        "duration": 5.1
    },
    {
        "text": "by the first line therapy that these",
        "start": 2884.14,
        "duration": 5.06
    },
    {
        "text": "patients receive so you can see that the",
        "start": 2885.64,
        "duration": 5.729
    },
    {
        "text": "the confidence intervals really are",
        "start": 2889.2,
        "duration": 4.26
    },
    {
        "text": "largely overlapping for many of these",
        "start": 2891.369,
        "duration": 4.381
    },
    {
        "text": "but I think we're getting to a point",
        "start": 2893.46,
        "duration": 4.659
    },
    {
        "text": "with latest data relief or we can start",
        "start": 2895.75,
        "duration": 4.77
    },
    {
        "text": "seeing separation of these curve and so",
        "start": 2898.119,
        "duration": 4.201
    },
    {
        "text": "this can really help it understand you",
        "start": 2900.52,
        "duration": 3.599
    },
    {
        "text": "know what are the what are the best",
        "start": 2902.32,
        "duration": 3.42
    },
    {
        "text": "combination what are the drugs that seem",
        "start": 2904.119,
        "duration": 4.23
    },
    {
        "text": "to be most effective and what are the",
        "start": 2905.74,
        "duration": 6.33
    },
    {
        "text": "different genomics that correspond to",
        "start": 2908.349,
        "duration": 6.031
    },
    {
        "text": "these types of response so do we see",
        "start": 2912.07,
        "duration": 3.81
    },
    {
        "text": "different mutations or different things",
        "start": 2914.38,
        "duration": 3.09
    },
    {
        "text": "popping up in a genomics data that",
        "start": 2915.88,
        "duration": 4.469
    },
    {
        "text": "correlate with better response and maybe",
        "start": 2917.47,
        "duration": 4.74
    },
    {
        "text": "we should be stratifying patients using",
        "start": 2920.349,
        "duration": 6.091
    },
    {
        "text": "those different markers so the path",
        "start": 2922.21,
        "duration": 6.03
    },
    {
        "text": "forward for this is to further analyze",
        "start": 2926.44,
        "duration": 3.899
    },
    {
        "text": "the data in conjunction with T Jen who's",
        "start": 2928.24,
        "duration": 3.84
    },
    {
        "text": "running a lot of peopie of Mattox for",
        "start": 2930.339,
        "duration": 5.481
    },
    {
        "text": "this and also with the MMRF itself",
        "start": 2932.08,
        "duration": 5.82
    },
    {
        "text": "clinical endpoint correlations with the",
        "start": 2935.82,
        "duration": 3.64
    },
    {
        "text": "molecular readouts like I mentioned will",
        "start": 2937.9,
        "duration": 2.87
    },
    {
        "text": "help",
        "start": 2939.46,
        "duration": 3.17
    },
    {
        "text": "get a better understanding of what",
        "start": 2940.77,
        "duration": 5.13
    },
    {
        "text": "markers are truly or possibly predictive",
        "start": 2942.63,
        "duration": 6.36
    },
    {
        "text": "and then look in a valid ation to see if",
        "start": 2945.9,
        "duration": 9.689
    },
    {
        "text": "that those same things can apply with",
        "start": 2948.99,
        "duration": 8.22
    },
    {
        "text": "the lung gases I'll just quickly go",
        "start": 2955.589,
        "duration": 4.311
    },
    {
        "text": "through this for lung and prostate I",
        "start": 2957.21,
        "duration": 5.639
    },
    {
        "text": "think in general we're looking for new",
        "start": 2959.9,
        "duration": 4.36
    },
    {
        "text": "driver segments of squamous cell",
        "start": 2962.849,
        "duration": 4.321
    },
    {
        "text": "carcinoma acquired an intrinsic",
        "start": 2964.26,
        "duration": 5.64
    },
    {
        "text": "resistance adenocarcinoma and also a",
        "start": 2967.17,
        "duration": 6.12
    },
    {
        "text": "very key focus on small cell lung cancer",
        "start": 2969.9,
        "duration": 6.87
    },
    {
        "text": "as well and so some of the work that's",
        "start": 2973.29,
        "duration": 5.34
    },
    {
        "text": "going on within the computational group",
        "start": 2976.77,
        "duration": 3.539
    },
    {
        "text": "is looking at some of the clinical data",
        "start": 2978.63,
        "duration": 3.51
    },
    {
        "text": "and that's coming in from the FDF our",
        "start": 2980.309,
        "duration": 4.081
    },
    {
        "text": "study and here it's looking at some of",
        "start": 2982.14,
        "duration": 4.199
    },
    {
        "text": "the predictive markers that are being",
        "start": 2984.39,
        "duration": 4.02
    },
    {
        "text": "proposed and these are some of the",
        "start": 2986.339,
        "duration": 3.691
    },
    {
        "text": "related to some of the fusions but also",
        "start": 2988.41,
        "duration": 5.28
    },
    {
        "text": "we had run a broad panel Foundation",
        "start": 2990.03,
        "duration": 5.039
    },
    {
        "text": "medicine panel as well so there are a",
        "start": 2993.69,
        "duration": 3.3
    },
    {
        "text": "few hundred other markers that are in",
        "start": 2995.069,
        "duration": 4.921
    },
    {
        "text": "there also pharmacodynamic markers had",
        "start": 2996.99,
        "duration": 5.19
    },
    {
        "text": "been tested in the previous clinical",
        "start": 2999.99,
        "duration": 5.01
    },
    {
        "text": "study as well as skin and tumor ithc",
        "start": 3002.18,
        "duration": 5.49
    },
    {
        "text": "marker and so all of this data has to be",
        "start": 3005.0,
        "duration": 6.21
    },
    {
        "text": "crunched within our group as well in",
        "start": 3007.67,
        "duration": 6.57
    },
    {
        "text": "addition to the clinical project we also",
        "start": 3011.21,
        "duration": 4.74
    },
    {
        "text": "have a project going on called the the",
        "start": 3014.24,
        "duration": 3.45
    },
    {
        "text": "pre Cancer Genome Atlas so this is a",
        "start": 3015.95,
        "duration": 4.2
    },
    {
        "text": "play on the TCGA this is pc da and",
        "start": 3017.69,
        "duration": 5.01
    },
    {
        "text": "there's a project going on with the",
        "start": 3020.15,
        "duration": 4.14
    },
    {
        "text": "collaborator of Boston University and",
        "start": 3022.7,
        "duration": 4.7
    },
    {
        "text": "this is the goal of this is to look at",
        "start": 3024.29,
        "duration": 6.69
    },
    {
        "text": "26 high-risk VD patient followed",
        "start": 3027.4,
        "duration": 6.88
    },
    {
        "text": "longitudinally with sequential airway",
        "start": 3030.98,
        "duration": 7.73
    },
    {
        "text": "brushes brushes and lesion sampling and",
        "start": 3034.28,
        "duration": 7.5
    },
    {
        "text": "then also perform RNA seek and exomes",
        "start": 3038.71,
        "duration": 4.629
    },
    {
        "text": "decoders sample you get a better",
        "start": 3041.78,
        "duration": 2.579
    },
    {
        "text": "understanding of what's actually",
        "start": 3043.339,
        "duration": 3.48
    },
    {
        "text": "changing during a during the progression",
        "start": 3044.359,
        "duration": 7.021
    },
    {
        "text": "of disease so related to this in a",
        "start": 3046.819,
        "duration": 6.661
    },
    {
        "text": "similar vein at least is that the",
        "start": 3051.38,
        "duration": 4.709
    },
    {
        "text": "project run in China this is the the",
        "start": 3053.48,
        "duration": 3.45
    },
    {
        "text": "China choiced",
        "start": 3056.089,
        "duration": 3.27
    },
    {
        "text": "study and this is being run with our J&J",
        "start": 3056.93,
        "duration": 5.85
    },
    {
        "text": "China collaborator so the goal here is",
        "start": 3059.359,
        "duration": 8.581
    },
    {
        "text": "250 patients 7 site targeting 125 Aetna",
        "start": 3062.78,
        "duration": 7.799
    },
    {
        "text": "carcinoma 125 squamous cell carcinoma",
        "start": 3067.94,
        "duration": 5.639
    },
    {
        "text": "and then also run our AC can DNA",
        "start": 3070.579,
        "duration": 5.601
    },
    {
        "text": "sequence",
        "start": 3073.579,
        "duration": 2.601
    },
    {
        "text": "in addition to this we have a couple",
        "start": 3079.19,
        "duration": 3.27
    },
    {
        "text": "discovery projects going on synthetic",
        "start": 3080.45,
        "duration": 4.649
    },
    {
        "text": "lethality is something that was proposed",
        "start": 3082.46,
        "duration": 4.589
    },
    {
        "text": "and we're moving forward with this is",
        "start": 3085.099,
        "duration": 3.801
    },
    {
        "text": "looking for identical identification",
        "start": 3087.049,
        "duration": 5.04
    },
    {
        "text": "loss-of-function alteration that can be",
        "start": 3088.9,
        "duration": 6.04
    },
    {
        "text": "used as classifiers for a functional",
        "start": 3092.089,
        "duration": 6.96
    },
    {
        "text": "paralog and so I'm going to that in a",
        "start": 3094.94,
        "duration": 6.419
    },
    {
        "text": "minute and then also looking at a signal",
        "start": 3099.049,
        "duration": 4.651
    },
    {
        "text": "peptide where we can look in gene",
        "start": 3101.359,
        "duration": 5.341
    },
    {
        "text": "expression databases to see if we can",
        "start": 3103.7,
        "duration": 6.18
    },
    {
        "text": "identify a signal peptides that have a",
        "start": 3106.7,
        "duration": 5.159
    },
    {
        "text": "particular domain which should",
        "start": 3109.88,
        "duration": 4.05
    },
    {
        "text": "differential expression between lung",
        "start": 3111.859,
        "duration": 7.081
    },
    {
        "text": "tumor vs. so just to jump into the goals",
        "start": 3113.93,
        "duration": 7.98
    },
    {
        "text": "of the PCD a project I mentioned the key",
        "start": 3118.94,
        "duration": 4.679
    },
    {
        "text": "questions here really are define the",
        "start": 3121.91,
        "duration": 5.069
    },
    {
        "text": "spectrum of genomic alterations that are",
        "start": 3123.619,
        "duration": 8.101
    },
    {
        "text": "changed from pre malignant identify the",
        "start": 3126.979,
        "duration": 6.3
    },
    {
        "text": "molecular alterations and pathways",
        "start": 3131.72,
        "duration": 4.309
    },
    {
        "text": "associated with lesion progression",
        "start": 3133.279,
        "duration": 4.891
    },
    {
        "text": "identify new candidate targets and this",
        "start": 3136.029,
        "duration": 4.09
    },
    {
        "text": "obviously feed into our discovery group",
        "start": 3138.17,
        "duration": 5.49
    },
    {
        "text": "and then refine and validate these",
        "start": 3140.119,
        "duration": 5.581
    },
    {
        "text": "genomic alterations associated with",
        "start": 3143.66,
        "duration": 4.47
    },
    {
        "text": "lesion progression using prospectively",
        "start": 3145.7,
        "duration": 6.029
    },
    {
        "text": "collected samples and then finally",
        "start": 3148.13,
        "duration": 5.55
    },
    {
        "text": "perform functional assays so this would",
        "start": 3151.729,
        "duration": 3.481
    },
    {
        "text": "be the follow-on to some of the",
        "start": 3153.68,
        "duration": 2.879
    },
    {
        "text": "discoveries you might make with this",
        "start": 3155.21,
        "duration": 6.059
    },
    {
        "text": "data the China choice study the key",
        "start": 3156.559,
        "duration": 6.841
    },
    {
        "text": "questions really fall into different",
        "start": 3161.269,
        "duration": 3.81
    },
    {
        "text": "categories here for gene expression or",
        "start": 3163.4,
        "duration": 2.969
    },
    {
        "text": "somatic alterations so for gene",
        "start": 3165.079,
        "duration": 2.78
    },
    {
        "text": "expression we can start looking for",
        "start": 3166.369,
        "duration": 4.561
    },
    {
        "text": "genes that are show unique expression",
        "start": 3167.859,
        "duration": 4.301
    },
    {
        "text": "profiles or were things that",
        "start": 3170.93,
        "duration": 2.689
    },
    {
        "text": "differentiate smokers and non-smokers",
        "start": 3172.16,
        "duration": 5.22
    },
    {
        "text": "and then for somatic alterations really",
        "start": 3173.619,
        "duration": 5.65
    },
    {
        "text": "understanding is there a difference",
        "start": 3177.38,
        "duration": 3.659
    },
    {
        "text": "between eastern and western populations",
        "start": 3179.269,
        "duration": 5.131
    },
    {
        "text": "we know from TCGA what to expect but",
        "start": 3181.039,
        "duration": 5.28
    },
    {
        "text": "that may not necessarily be what we find",
        "start": 3184.4,
        "duration": 7.02
    },
    {
        "text": "it and it's China study and also can can",
        "start": 3186.319,
        "duration": 6.99
    },
    {
        "text": "we develop classifiers have as we would",
        "start": 3191.42,
        "duration": 3.389
    },
    {
        "text": "for any of the clinical studies we'll",
        "start": 3193.309,
        "duration": 3.671
    },
    {
        "text": "running",
        "start": 3194.809,
        "duration": 3.641
    },
    {
        "text": "and then finally are there novel",
        "start": 3196.98,
        "duration": 3.36
    },
    {
        "text": "recurrent fusion events or can we",
        "start": 3198.45,
        "duration": 7.77
    },
    {
        "text": "identify key resistance marker synthetic",
        "start": 3200.34,
        "duration": 9.18
    },
    {
        "text": "lethality as I mentioned this is where",
        "start": 3206.22,
        "duration": 5.22
    },
    {
        "text": "the functional inhibition of one target",
        "start": 3209.52,
        "duration": 6.93
    },
    {
        "text": "is its efficacious exclusively in cells",
        "start": 3211.44,
        "duration": 8.88
    },
    {
        "text": "with a second functional division so the",
        "start": 3216.45,
        "duration": 6.93
    },
    {
        "text": "diagram here just illustrates if if you",
        "start": 3220.32,
        "duration": 5.73
    },
    {
        "text": "have a wild-type cell if you knock out",
        "start": 3223.38,
        "duration": 5.1
    },
    {
        "text": "one of the two partners you see no",
        "start": 3226.05,
        "duration": 6.21
    },
    {
        "text": "effect on viability however if you knock",
        "start": 3228.48,
        "duration": 9.63
    },
    {
        "text": "out a gene in a Cell that already has a",
        "start": 3232.26,
        "duration": 9.21
    },
    {
        "text": "mutant in a different gene you actually",
        "start": 3238.11,
        "duration": 5.22
    },
    {
        "text": "can induce solve that so this is the",
        "start": 3241.47,
        "duration": 5.48
    },
    {
        "text": "concept behind ally this is not a new",
        "start": 3243.33,
        "duration": 7.56
    },
    {
        "text": "concept but we're looking at this in the",
        "start": 3246.95,
        "duration": 5.62
    },
    {
        "text": "context of some of the new datasets that",
        "start": 3250.89,
        "duration": 3.81
    },
    {
        "text": "have come out so trying to leverage from",
        "start": 3252.57,
        "duration": 4.86
    },
    {
        "text": "the public data at TCGA and others where",
        "start": 3254.7,
        "duration": 4.56
    },
    {
        "text": "we can start looking specifically at",
        "start": 3257.43,
        "duration": 4.8
    },
    {
        "text": "this using both gene expression and the",
        "start": 3259.26,
        "duration": 5.85
    },
    {
        "text": "somatic mutation data from from the DNA",
        "start": 3262.23,
        "duration": 4.41
    },
    {
        "text": "seq experiment that have been around and",
        "start": 3265.11,
        "duration": 3.3
    },
    {
        "text": "see if we can tease out some of this",
        "start": 3266.64,
        "duration": 4.02
    },
    {
        "text": "information and perhaps propose new",
        "start": 3268.41,
        "duration": 8.01
    },
    {
        "text": "target for the lung cancer so for the",
        "start": 3270.66,
        "duration": 6.16
    },
    {
        "text": "press",
        "start": 3276.42,
        "duration": 3.22
    },
    {
        "text": "I just have a few slides but as Nick",
        "start": 3276.82,
        "duration": 4.83
    },
    {
        "text": "mentioned I think a lot of the clinical",
        "start": 3279.64,
        "duration": 3.72
    },
    {
        "text": "focus right now is around the a our axis",
        "start": 3281.65,
        "duration": 5.43
    },
    {
        "text": "of prostate cancer so targeting androgen",
        "start": 3283.36,
        "duration": 7.2
    },
    {
        "text": "receptor signaling and so here we're",
        "start": 3287.08,
        "duration": 5.91
    },
    {
        "text": "looking for computation are we looking",
        "start": 3290.56,
        "duration": 4.53
    },
    {
        "text": "to identify those patients that may be",
        "start": 3292.99,
        "duration": 4.35
    },
    {
        "text": "at high risk so a lot of patients that",
        "start": 3295.09,
        "duration": 3.63
    },
    {
        "text": "have prostate cancer won't necessarily",
        "start": 3297.34,
        "duration": 5.07
    },
    {
        "text": "die from prostate cancer so a lot of the",
        "start": 3298.72,
        "duration": 5.4
    },
    {
        "text": "work here is really trying to identify",
        "start": 3302.41,
        "duration": 3.24
    },
    {
        "text": "those patients using molecular",
        "start": 3304.12,
        "duration": 4.47
    },
    {
        "text": "signatures or other asses that can help",
        "start": 3305.65,
        "duration": 5.16
    },
    {
        "text": "us distinguish those patients that would",
        "start": 3308.59,
        "duration": 3.93
    },
    {
        "text": "be high-risk from those patients with",
        "start": 3310.81,
        "duration": 5.76
    },
    {
        "text": "with indolent disease so we're trying to",
        "start": 3312.52,
        "duration": 8.09
    },
    {
        "text": "really focus on that using computational",
        "start": 3316.57,
        "duration": 4.04
    },
    {
        "text": "so just to go into this a little bit as",
        "start": 3322.86,
        "duration": 5.32
    },
    {
        "text": "I said understanding key resistance",
        "start": 3326.68,
        "duration": 3.66
    },
    {
        "text": "mechanisms it's also important as it is",
        "start": 3328.18,
        "duration": 4.68
    },
    {
        "text": "in teen so if we can start to tease them",
        "start": 3330.34,
        "duration": 3.69
    },
    {
        "text": "out from the clinical data were",
        "start": 3332.86,
        "duration": 2.4
    },
    {
        "text": "generating that would certainly help",
        "start": 3334.03,
        "duration": 4.95
    },
    {
        "text": "with the next round of drug development",
        "start": 3335.26,
        "duration": 6.45
    },
    {
        "text": "that we're doing and also trying to",
        "start": 3338.98,
        "duration": 5.67
    },
    {
        "text": "identify these high risk markers and",
        "start": 3341.71,
        "duration": 5.55
    },
    {
        "text": "pull up that population and try and",
        "start": 3344.65,
        "duration": 7.98
    },
    {
        "text": "treat them more aggressively the last",
        "start": 3347.26,
        "duration": 6.96
    },
    {
        "text": "thing on the list here is characterizing",
        "start": 3352.63,
        "duration": 3.71
    },
    {
        "text": "IO and checkpoint gene expression so",
        "start": 3354.22,
        "duration": 5.64
    },
    {
        "text": "just to highlight that here looking at",
        "start": 3356.34,
        "duration": 5.35
    },
    {
        "text": "expression profiling of immune cell",
        "start": 3359.86,
        "duration": 3.75
    },
    {
        "text": "populations in tumors and peripheral",
        "start": 3361.69,
        "duration": 4.92
    },
    {
        "text": "blood really can help us understand the",
        "start": 3363.61,
        "duration": 6.15
    },
    {
        "text": "IO make up of a particular tumor and",
        "start": 3366.61,
        "duration": 5.13
    },
    {
        "text": "perhaps understand better what's going",
        "start": 3369.76,
        "duration": 3.69
    },
    {
        "text": "to be predictive of patients that are",
        "start": 3371.74,
        "duration": 5.07
    },
    {
        "text": "more likely respond or drugs or patients",
        "start": 3373.45,
        "duration": 5.16
    },
    {
        "text": "that would benefit from some combination",
        "start": 3376.81,
        "duration": 7.38
    },
    {
        "text": "within IO therapy so",
        "start": 3378.61,
        "duration": 7.259
    },
    {
        "text": "some of the cross task projects and then",
        "start": 3384.19,
        "duration": 6.51
    },
    {
        "text": "I'll end with this so obviously we're",
        "start": 3385.869,
        "duration": 6.151
    },
    {
        "text": "working across many different disease",
        "start": 3390.7,
        "duration": 3.57
    },
    {
        "text": "areas but there is a common thread in",
        "start": 3392.02,
        "duration": 5.69
    },
    {
        "text": "the types of the types of computational",
        "start": 3394.27,
        "duration": 5.46
    },
    {
        "text": "infrastructure that we need to do this",
        "start": 3397.71,
        "duration": 4.629
    },
    {
        "text": "work so we'd like to leverage both",
        "start": 3399.73,
        "duration": 4.32
    },
    {
        "text": "external and internal data and",
        "start": 3402.339,
        "duration": 4.651
    },
    {
        "text": "analytical methodologies to deliver on",
        "start": 3404.05,
        "duration": 5.16
    },
    {
        "text": "the - objectives effectively communicate",
        "start": 3406.99,
        "duration": 4.8
    },
    {
        "text": "within and across staff as store data in",
        "start": 3409.21,
        "duration": 4.26
    },
    {
        "text": "a compliant way and then standardize",
        "start": 3411.79,
        "duration": 5.76
    },
    {
        "text": "reproducible research so one of the",
        "start": 3413.47,
        "duration": 8.22
    },
    {
        "text": "things that we've built is this this NGS",
        "start": 3417.55,
        "duration": 6.96
    },
    {
        "text": "pipeline and this is actually leveraging",
        "start": 3421.69,
        "duration": 4.919
    },
    {
        "text": "the Amazon Cloud I know when you're here",
        "start": 3424.51,
        "duration": 3.69
    },
    {
        "text": "you probably have access to large",
        "start": 3426.609,
        "duration": 4.201
    },
    {
        "text": "clusters and somebody maintains that for",
        "start": 3428.2,
        "duration": 4.879
    },
    {
        "text": "you in industry we have the same",
        "start": 3430.81,
        "duration": 3.809
    },
    {
        "text": "infrastructure except it's very",
        "start": 3433.079,
        "duration": 3.971
    },
    {
        "text": "expensive to maintain its very upgrade",
        "start": 3434.619,
        "duration": 5.21
    },
    {
        "text": "and over time it's very costly so",
        "start": 3437.05,
        "duration": 4.92
    },
    {
        "text": "something that's been commoditized is",
        "start": 3439.829,
        "duration": 4.811
    },
    {
        "text": "this high throughput type analysis",
        "start": 3441.97,
        "duration": 5.04
    },
    {
        "text": "analysis that you can farm out to Amazon",
        "start": 3444.64,
        "duration": 5.01
    },
    {
        "text": "or other cloud providers and this is",
        "start": 3447.01,
        "duration": 4.05
    },
    {
        "text": "something we've embraced and really",
        "start": 3449.65,
        "duration": 3.6
    },
    {
        "text": "driven down the cost of doing it like a",
        "start": 3451.06,
        "duration": 5.99
    },
    {
        "text": "research so this just illustrates the",
        "start": 3453.25,
        "duration": 6.599
    },
    {
        "text": "system we've set up to take advantage of",
        "start": 3457.05,
        "duration": 6.039
    },
    {
        "text": "this really infinitely scalable system",
        "start": 3459.849,
        "duration": 7.561
    },
    {
        "text": "for doing data analysis and then",
        "start": 3463.089,
        "duration": 6.301
    },
    {
        "text": "internally we've built this omics data",
        "start": 3467.41,
        "duration": 3.87
    },
    {
        "text": "capture system and really that where",
        "start": 3469.39,
        "duration": 4.77
    },
    {
        "text": "this becomes important is when people",
        "start": 3471.28,
        "duration": 4.95
    },
    {
        "text": "have questions about previous clinical",
        "start": 3474.16,
        "duration": 4.37
    },
    {
        "text": "studies or previous preclinical studies",
        "start": 3476.23,
        "duration": 4.889
    },
    {
        "text": "oftentimes the data in the past would be",
        "start": 3478.53,
        "duration": 3.94
    },
    {
        "text": "squirreled away on some of hard drive",
        "start": 3481.119,
        "duration": 3.811
    },
    {
        "text": "somewhere even in academia things are",
        "start": 3482.47,
        "duration": 4.29
    },
    {
        "text": "very siloed depending on what lab you",
        "start": 3484.93,
        "duration": 4.98
    },
    {
        "text": "might be in so this is an effort to",
        "start": 3486.76,
        "duration": 5.25
    },
    {
        "text": "really harmonize how are storing data",
        "start": 3489.91,
        "duration": 4.56
    },
    {
        "text": "harmonized how we're querying that data",
        "start": 3492.01,
        "duration": 4.44
    },
    {
        "text": "and make it accessible not just to bench",
        "start": 3494.47,
        "duration": 3.54
    },
    {
        "text": "scientists who have questions but also",
        "start": 3496.45,
        "duration": 4.23
    },
    {
        "text": "the computational biologists who might",
        "start": 3498.01,
        "duration": 5.609
    },
    {
        "text": "be able to run as more advanced queries",
        "start": 3500.68,
        "duration": 5.399
    },
    {
        "text": "on so in addition to a Spotfire",
        "start": 3503.619,
        "duration": 5.181
    },
    {
        "text": "interface where we have a very nice",
        "start": 3506.079,
        "duration": 6.421
    },
    {
        "text": "point-and-click style way to generate",
        "start": 3508.8,
        "duration": 5.2
    },
    {
        "text": "plots and things like that filter data",
        "start": 3512.5,
        "duration": 3.42
    },
    {
        "text": "we also have an API that allows",
        "start": 3514.0,
        "duration": 3.66
    },
    {
        "text": "programmatic access that",
        "start": 3515.92,
        "duration": 3.57
    },
    {
        "text": "actually accommodates the people in my",
        "start": 3517.66,
        "duration": 3.75
    },
    {
        "text": "group who really want to dig into the",
        "start": 3519.49,
        "duration": 3.51
    },
    {
        "text": "data and maybe slice and dice it many",
        "start": 3521.41,
        "duration": 5.91
    },
    {
        "text": "different ways so this is just an",
        "start": 3523.0,
        "duration": 7.11
    },
    {
        "text": "example of a heme cell line profiling",
        "start": 3527.32,
        "duration": 4.47
    },
    {
        "text": "project that we have in here we have a",
        "start": 3530.11,
        "duration": 3.06
    },
    {
        "text": "gene expression profiling data by",
        "start": 3531.79,
        "duration": 3.93
    },
    {
        "text": "microarray DNA see car NAC and flow",
        "start": 3533.17,
        "duration": 4.89
    },
    {
        "text": "cytometry data all combined and this",
        "start": 3535.72,
        "duration": 4.14
    },
    {
        "text": "allows very quick manipulation of this",
        "start": 3538.06,
        "duration": 3.99
    },
    {
        "text": "data and filtering so that you can",
        "start": 3539.86,
        "duration": 5.73
    },
    {
        "text": "quickly get to answers when in the past",
        "start": 3542.05,
        "duration": 6.44
    },
    {
        "text": "it would have been much more difficult",
        "start": 3545.59,
        "duration": 2.9
    },
    {
        "text": "and finally I'll end on this this is",
        "start": 3549.27,
        "duration": 5.29
    },
    {
        "text": "some of the efforts within our",
        "start": 3552.1,
        "duration": 4.43
    },
    {
        "text": "organization and really company-wide",
        "start": 3554.56,
        "duration": 5.66
    },
    {
        "text": "this idea of reproducible research or",
        "start": 3556.53,
        "duration": 7.39
    },
    {
        "text": "discovery data integrity this DDI and",
        "start": 3560.22,
        "duration": 5.2
    },
    {
        "text": "this is really important not just for us",
        "start": 3563.92,
        "duration": 3.09
    },
    {
        "text": "but I think also to the academic",
        "start": 3565.42,
        "duration": 3.24
    },
    {
        "text": "community if you read some of the papers",
        "start": 3567.01,
        "duration": 4.56
    },
    {
        "text": "that show you know how your reproducible",
        "start": 3568.66,
        "duration": 5.04
    },
    {
        "text": "a lot of the data analysis and really",
        "start": 3571.57,
        "duration": 5.04
    },
    {
        "text": "studies have been that have been",
        "start": 3573.7,
        "duration": 4.95
    },
    {
        "text": "published I think this really gets at",
        "start": 3576.61,
        "duration": 4.44
    },
    {
        "text": "the heart of that really having analyses",
        "start": 3578.65,
        "duration": 5.1
    },
    {
        "text": "that you that you could hand the script",
        "start": 3581.05,
        "duration": 5.25
    },
    {
        "text": "to anyone they could rerun it and this",
        "start": 3583.75,
        "duration": 3.72
    },
    {
        "text": "is a concept that I think it's been",
        "start": 3586.3,
        "duration": 4.65
    },
    {
        "text": "embraced by some labs but not all but I",
        "start": 3587.47,
        "duration": 5.01
    },
    {
        "text": "think it really gets at the heart of the",
        "start": 3590.95,
        "duration": 3.66
    },
    {
        "text": "whole idea of discovery data integrity",
        "start": 3592.48,
        "duration": 3.99
    },
    {
        "text": "though for every plot that we generate",
        "start": 3594.61,
        "duration": 3.54
    },
    {
        "text": "for every report that we write we can",
        "start": 3596.47,
        "duration": 3.21
    },
    {
        "text": "actually trace it back to the original",
        "start": 3598.15,
        "duration": 3.69
    },
    {
        "text": "raw data and the script that generated",
        "start": 3599.68,
        "duration": 4.65
    },
    {
        "text": "it so for a lot of the work we do is in",
        "start": 3601.84,
        "duration": 5.7
    },
    {
        "text": "our and this is a really nice fit for",
        "start": 3604.33,
        "duration": 5.04
    },
    {
        "text": "something like this everything is",
        "start": 3607.54,
        "duration": 3.03
    },
    {
        "text": "scripted and everything and we know",
        "start": 3609.37,
        "duration": 6.36
    },
    {
        "text": "exactly where all the data is so just to",
        "start": 3610.57,
        "duration": 7.65
    },
    {
        "text": "summarize the death that's alignment",
        "start": 3615.73,
        "duration": 5.34
    },
    {
        "text": "really keeps project focused and I think",
        "start": 3618.22,
        "duration": 6.69
    },
    {
        "text": "it keeps focus within the group many",
        "start": 3621.07,
        "duration": 6.15
    },
    {
        "text": "clinical studies incorporate omics or",
        "start": 3624.91,
        "duration": 3.9
    },
    {
        "text": "high dimensional data readouts and so",
        "start": 3627.22,
        "duration": 3.99
    },
    {
        "text": "this is all work that comes to the",
        "start": 3628.81,
        "duration": 4.53
    },
    {
        "text": "computational biology group to process",
        "start": 3631.21,
        "duration": 5.19
    },
    {
        "text": "and analyze and help interpret disease",
        "start": 3633.34,
        "duration": 5.46
    },
    {
        "text": "interception as a key strategy of the",
        "start": 3636.4,
        "duration": 5.04
    },
    {
        "text": "gases and immuno Oncology will certainly",
        "start": 3638.8,
        "duration": 4.11
    },
    {
        "text": "play an important role in cancer",
        "start": 3641.44,
        "duration": 3.78
    },
    {
        "text": "treatment going forward so understanding",
        "start": 3642.91,
        "duration": 4.26
    },
    {
        "text": "what is it or what do we need to be",
        "start": 3645.22,
        "duration": 4.19
    },
    {
        "text": "looking for in these assays results",
        "start": 3647.17,
        "duration": 4.74
    },
    {
        "text": "tease out - really",
        "start": 3649.41,
        "duration": 4.66
    },
    {
        "text": "how to best treat patient it's something",
        "start": 3651.91,
        "duration": 5.1
    },
    {
        "text": "that we have a really important thing to",
        "start": 3654.07,
        "duration": 6.32
    },
    {
        "text": "keep in mind as we're doing it",
        "start": 3657.01,
        "duration": 3.38
    },
    {
        "text": "computational challenges biomarker",
        "start": 3660.91,
        "duration": 4.68
    },
    {
        "text": "development you know here hear a lot",
        "start": 3663.31,
        "duration": 5.04
    },
    {
        "text": "about Big Data you may see Johnson",
        "start": 3665.59,
        "duration": 4.35
    },
    {
        "text": "Johnson and other pharma companies and",
        "start": 3668.35,
        "duration": 3.12
    },
    {
        "text": "thinking you know we're sitting at the",
        "start": 3669.94,
        "duration": 3.45
    },
    {
        "text": "sitting on this mountain of data and in",
        "start": 3671.47,
        "duration": 4.53
    },
    {
        "text": "some ways we are but in many cases the",
        "start": 3673.39,
        "duration": 4.91
    },
    {
        "text": "big data is really the assets in itself",
        "start": 3676.0,
        "duration": 5.28
    },
    {
        "text": "the data set themselves tend to be",
        "start": 3678.3,
        "duration": 5.17
    },
    {
        "text": "fairly small for some of our our phase",
        "start": 3681.28,
        "duration": 5.16
    },
    {
        "text": "one study so the question really is how",
        "start": 3683.47,
        "duration": 5.25
    },
    {
        "text": "do we get as much information as we can",
        "start": 3686.44,
        "duration": 4.53
    },
    {
        "text": "from the studies knowing that in some",
        "start": 3688.72,
        "duration": 4.74
    },
    {
        "text": "cases they're often under power to",
        "start": 3690.97,
        "duration": 5.91
    },
    {
        "text": "actually detect some signal and then",
        "start": 3693.46,
        "duration": 5.37
    },
    {
        "text": "from there generate a hypothesis that we",
        "start": 3696.88,
        "duration": 4.83
    },
    {
        "text": "can then prospectively test another",
        "start": 3698.83,
        "duration": 4.44
    },
    {
        "text": "question that comes up is global versus",
        "start": 3701.71,
        "duration": 6.05
    },
    {
        "text": "targeted analyses so do you sacrifice",
        "start": 3703.27,
        "duration": 6.92
    },
    {
        "text": "depth for breath or vice versa",
        "start": 3707.76,
        "duration": 5.5
    },
    {
        "text": "so when you're talking about NGS",
        "start": 3710.19,
        "duration": 4.63
    },
    {
        "text": "approaches for example do you go at the",
        "start": 3713.26,
        "duration": 2.58
    },
    {
        "text": "target of panel where you can get a",
        "start": 3714.82,
        "duration": 2.43
    },
    {
        "text": "thousand x coverage or do you do",
        "start": 3715.84,
        "duration": 5.55
    },
    {
        "text": "genome-wide or X on Y and risk missing",
        "start": 3717.25,
        "duration": 6.39
    },
    {
        "text": "things that may be showing up at a very",
        "start": 3721.39,
        "duration": 6.09
    },
    {
        "text": "low level and again are the studies",
        "start": 3723.64,
        "duration": 6.54
    },
    {
        "text": "sufficiently power within me know",
        "start": 3727.48,
        "duration": 4.05
    },
    {
        "text": "oncology some of the computational",
        "start": 3730.18,
        "duration": 2.82
    },
    {
        "text": "challenges are really the the novel",
        "start": 3731.53,
        "duration": 3.69
    },
    {
        "text": "analytical methods that are needed some",
        "start": 3733.0,
        "duration": 4.11
    },
    {
        "text": "of these have very specific readouts and",
        "start": 3735.22,
        "duration": 4.41
    },
    {
        "text": "very specific analytical approaches and",
        "start": 3737.11,
        "duration": 4.38
    },
    {
        "text": "I like in the work that's going on in",
        "start": 3739.63,
        "duration": 4.05
    },
    {
        "text": "immuno oncology right now to some of the",
        "start": 3741.49,
        "duration": 3.8
    },
    {
        "text": "early days of my career development",
        "start": 3743.68,
        "duration": 4.11
    },
    {
        "text": "where it's a bit of the Wild West where",
        "start": 3745.29,
        "duration": 4.96
    },
    {
        "text": "we have many academic groups publishing",
        "start": 3747.79,
        "duration": 4.5
    },
    {
        "text": "different methods for analyzing this",
        "start": 3750.25,
        "duration": 4.68
    },
    {
        "text": "data but in reality we don't really have",
        "start": 3752.29,
        "duration": 6.33
    },
    {
        "text": "a consistent way to look and query this",
        "start": 3754.93,
        "duration": 9.27
    },
    {
        "text": "data statistically for tumor",
        "start": 3758.62,
        "duration": 7.32
    },
    {
        "text": "microenvironment the sample",
        "start": 3764.2,
        "duration": 4.14
    },
    {
        "text": "heterogeneity in really confound",
        "start": 3765.94,
        "duration": 5.88
    },
    {
        "text": "analyses and for disease interception",
        "start": 3768.34,
        "duration": 7.71
    },
    {
        "text": "and minimal residual disease definitions",
        "start": 3771.82,
        "duration": 6.75
    },
    {
        "text": "of pre malignancy and MRD are not really",
        "start": 3776.05,
        "duration": 4.77
    },
    {
        "text": "yet standardized so we need to get to as",
        "start": 3778.57,
        "duration": 4.23
    },
    {
        "text": "a community you get to a point where",
        "start": 3780.82,
        "duration": 3.9
    },
    {
        "text": "these things really are standardized",
        "start": 3782.8,
        "duration": 3.66
    },
    {
        "text": "you have standard methodologies that are",
        "start": 3784.72,
        "duration": 4.5
    },
    {
        "text": "applied and I think that will help us on",
        "start": 3786.46,
        "duration": 4.05
    },
    {
        "text": "the computational side when we're",
        "start": 3789.22,
        "duration": 4.41
    },
    {
        "text": "analyzing this data so with that I'll",
        "start": 3790.51,
        "duration": 5.78
    },
    {
        "text": "just put the acknowledgments up and",
        "start": 3793.63,
        "duration": 4.44
    },
    {
        "text": "highlight the three people in my group",
        "start": 3796.29,
        "duration": 3.64
    },
    {
        "text": "the computational biology group listed",
        "start": 3798.07,
        "duration": 2.37
    },
    {
        "text": "here",
        "start": 3799.93,
        "duration": 2.58
    },
    {
        "text": "Tina cast me up like normally and Chris",
        "start": 3800.44,
        "duration": 5.7
    },
    {
        "text": "boy and then also the leads of each one",
        "start": 3802.51,
        "duration": 5.25
    },
    {
        "text": "of the data within our translational",
        "start": 3806.14,
        "duration": 3.42
    },
    {
        "text": "research group are underlined here so",
        "start": 3807.76,
        "duration": 4.589
    },
    {
        "text": "Kate's a surly seemed that they were",
        "start": 3809.56,
        "duration": 4.77
    },
    {
        "text": "achieve lead prostate death and Sue so",
        "start": 3812.349,
        "duration": 3.931
    },
    {
        "text": "Platero it leads to lung death and so",
        "start": 3814.33,
        "duration": 5.6
    },
    {
        "text": "they're all responsible for the project",
        "start": 3816.28,
        "duration": 3.65
    },
    {
        "text": "so yes that Jantzen use are to do most",
        "start": 3838.8,
        "duration": 24.46
    },
    {
        "text": "of the analysis but my question is I've",
        "start": 3857.65,
        "duration": 9.24
    },
    {
        "text": "heard that do you need to do some robust",
        "start": 3863.26,
        "duration": 6.12
    },
    {
        "text": "tests when you're using our packages",
        "start": 3866.89,
        "duration": 5.91
    },
    {
        "text": "because I know that some some some",
        "start": 3869.38,
        "duration": 6.63
    },
    {
        "text": "companies they require to do that yeah",
        "start": 3872.8,
        "duration": 5.91
    },
    {
        "text": "yeah that's a good question so typically",
        "start": 3876.01,
        "duration": 5.04
    },
    {
        "text": "for the clinical stats group they use",
        "start": 3878.71,
        "duration": 8.43
    },
    {
        "text": "sat with are a lot of the functionality",
        "start": 3881.05,
        "duration": 10.5
    },
    {
        "text": "that present there is not available so",
        "start": 3887.14,
        "duration": 7.05
    },
    {
        "text": "if you look at something like bloom limo",
        "start": 3891.55,
        "duration": 4.799
    },
    {
        "text": "or something for doing rna-seq analysis",
        "start": 3894.19,
        "duration": 4.89
    },
    {
        "text": "there is no equivalent so the",
        "start": 3896.349,
        "duration": 4.651
    },
    {
        "text": "evaluations we do just make sure",
        "start": 3899.08,
        "duration": 4.56
    },
    {
        "text": "internally that the version of our we're",
        "start": 3901.0,
        "duration": 4.109
    },
    {
        "text": "using a standardized and that we're all",
        "start": 3903.64,
        "duration": 4.83
    },
    {
        "text": "using the same version of boom so this",
        "start": 3905.109,
        "duration": 6.721
    },
    {
        "text": "is something we do internally a lot of",
        "start": 3908.47,
        "duration": 4.889
    },
    {
        "text": "the work we do here is exploratory as",
        "start": 3911.83,
        "duration": 4.05
    },
    {
        "text": "well so we don't necessarily have the",
        "start": 3913.359,
        "duration": 5.241
    },
    {
        "text": "same rigor that's necessary",
        "start": 3915.88,
        "duration": 4.64
    },
    {
        "text": "dealing with things that will end up in",
        "start": 3918.6,
        "duration": 3.99
    },
    {
        "text": "a clinical study report that gets filed",
        "start": 3920.52,
        "duration": 16.08
    },
    {
        "text": "with you what proportion of the current",
        "start": 3922.59,
        "duration": 18.84
    },
    {
        "text": "efforts are moving away from say",
        "start": 3936.6,
        "duration": 8.07
    },
    {
        "text": "computer aided drug design towards say",
        "start": 3941.43,
        "duration": 4.65
    },
    {
        "text": "one of these therapeutics that you",
        "start": 3944.67,
        "duration": 5.79
    },
    {
        "text": "mentioned sorry so so you described a",
        "start": 3946.08,
        "duration": 6.66
    },
    {
        "text": "couple of these projects so of course",
        "start": 3950.46,
        "duration": 4.5
    },
    {
        "text": "traditional ways the you know after",
        "start": 3952.74,
        "duration": 4.23
    },
    {
        "text": "these initial analysis then in the",
        "start": 3954.96,
        "duration": 3.75
    },
    {
        "text": "development stage you would look forward",
        "start": 3956.97,
        "duration": 3.66
    },
    {
        "text": "you know towards drug screening and so",
        "start": 3958.71,
        "duration": 2.4
    },
    {
        "text": "forth",
        "start": 3960.63,
        "duration": 4.53
    },
    {
        "text": "but then you also mentioned um moving",
        "start": 3961.11,
        "duration": 6.0
    },
    {
        "text": "away from the biomarker analysis I'm",
        "start": 3965.16,
        "duration": 3.66
    },
    {
        "text": "talking towards the you know the",
        "start": 3967.11,
        "duration": 4.17
    },
    {
        "text": "targeted therapeutics and such so what",
        "start": 3968.82,
        "duration": 4.53
    },
    {
        "text": "proportion of these current efforts are",
        "start": 3971.28,
        "duration": 5.42
    },
    {
        "text": "or that as you mentioned asked are",
        "start": 3973.35,
        "duration": 7.62
    },
    {
        "text": "looking in into these new therapeutics",
        "start": 3976.7,
        "duration": 6.46
    },
    {
        "text": "versus just the traditional computer",
        "start": 3980.97,
        "duration": 4.89
    },
    {
        "text": "aided drug design yeah so I think I get",
        "start": 3983.16,
        "duration": 5.4
    },
    {
        "text": "it your question to it so I think this",
        "start": 3985.86,
        "duration": 3.99
    },
    {
        "text": "is question partly about the small",
        "start": 3988.56,
        "duration": 6.08
    },
    {
        "text": "molecule development a lot of the assets",
        "start": 3989.85,
        "duration": 8.64
    },
    {
        "text": "actually large if you look at something",
        "start": 3994.64,
        "duration": 15.22
    },
    {
        "text": "like ibrutinib we've licensed that in so",
        "start": 3998.49,
        "duration": 16.22
    },
    {
        "text": "we also have these k rat b12 the",
        "start": 4009.86,
        "duration": 8.88
    },
    {
        "text": "compound that was that was just that",
        "start": 4014.71,
        "duration": 6.01
    },
    {
        "text": "will be coming online I think there will",
        "start": 4018.74,
        "duration": 4.35
    },
    {
        "text": "be some of this development as well that",
        "start": 4020.72,
        "duration": 8.04
    },
    {
        "text": "may be necessary so I'd say the the the",
        "start": 4023.09,
        "duration": 7.59
    },
    {
        "text": "requirement is diminishing",
        "start": 4028.76,
        "duration": 4.02
    },
    {
        "text": "I think we're getting away from small",
        "start": 4030.68,
        "duration": 5.61
    },
    {
        "text": "molecule but but not completely that's",
        "start": 4032.78,
        "duration": 5.81
    },
    {
        "text": "fair",
        "start": 4036.29,
        "duration": 2.3
    },
    {
        "text": "change this and ask like a general",
        "start": 4047.98,
        "duration": 6.07
    },
    {
        "text": "question for the interns and put posters",
        "start": 4050.6,
        "duration": 5.37
    },
    {
        "text": "and people who start working in your",
        "start": 4054.05,
        "duration": 5.19
    },
    {
        "text": "company any company there's always been",
        "start": 4055.97,
        "duration": 5.28
    },
    {
        "text": "the concern of the freedom to publish",
        "start": 4059.24,
        "duration": 4.35
    },
    {
        "text": "the result of the process it delays in",
        "start": 4061.25,
        "duration": 5.55
    },
    {
        "text": "publishing and can you miss the first",
        "start": 4063.59,
        "duration": 5.64
    },
    {
        "text": "part of Utah grad was that otherwise it",
        "start": 4066.8,
        "duration": 4.319
    },
    {
        "text": "would be that great idea to discuss that",
        "start": 4069.23,
        "duration": 3.87
    },
    {
        "text": "yeah yeah so I think it's a good",
        "start": 4071.119,
        "duration": 5.311
    },
    {
        "text": "question I think it's J&J I think really",
        "start": 4073.1,
        "duration": 5.43
    },
    {
        "text": "goes out of their way to say publishes",
        "start": 4076.43,
        "duration": 4.41
    },
    {
        "text": "much there are certain things where",
        "start": 4078.53,
        "duration": 3.75
    },
    {
        "text": "they're always going to be restrictions",
        "start": 4080.84,
        "duration": 2.67
    },
    {
        "text": "right so if you're talking about one of",
        "start": 4082.28,
        "duration": 3.06
    },
    {
        "text": "the compounds it does have to go through",
        "start": 4083.51,
        "duration": 4.23
    },
    {
        "text": "some process but in general if you're",
        "start": 4085.34,
        "duration": 5.25
    },
    {
        "text": "doing other types of research that don't",
        "start": 4087.74,
        "duration": 4.98
    },
    {
        "text": "necessarily impact the particular drug",
        "start": 4090.59,
        "duration": 4.7
    },
    {
        "text": "or a particular development of a drug",
        "start": 4092.72,
        "duration": 6.3
    },
    {
        "text": "there is broad freedom to publish and",
        "start": 4095.29,
        "duration": 6.04
    },
    {
        "text": "it's actually encouraged it does help",
        "start": 4099.02,
        "duration": 3.96
    },
    {
        "text": "you know attract other people for the",
        "start": 4101.33,
        "duration": 4.409
    },
    {
        "text": "company that are good for the clinical",
        "start": 4102.98,
        "duration": 4.62
    },
    {
        "text": "studies themselves you know obviously we",
        "start": 4105.739,
        "duration": 4.141
    },
    {
        "text": "try and again on as many of these",
        "start": 4107.6,
        "duration": 4.409
    },
    {
        "text": "publications as possible as we're doing",
        "start": 4109.88,
        "duration": 4.109
    },
    {
        "text": "the work here you know obviously we were",
        "start": 4112.009,
        "duration": 4.531
    },
    {
        "text": "feel entitled to get on these",
        "start": 4113.989,
        "duration": 6.361
    },
    {
        "text": "publications but but yeah there's there",
        "start": 4116.54,
        "duration": 5.19
    },
    {
        "text": "is some delay in getting on these",
        "start": 4120.35,
        "duration": 3.92
    },
    {
        "text": "clinical",
        "start": 4121.73,
        "duration": 2.54
    },
    {
        "text": "that's right and I should mention we do",
        "start": 4153.989,
        "duration": 5.02
    },
    {
        "text": "have an open postdoc position now so if",
        "start": 4156.519,
        "duration": 4.2
    },
    {
        "text": "anyone is interested or if you're",
        "start": 4159.009,
        "duration": 4.35
    },
    {
        "text": "finishing soon or you know other people",
        "start": 4160.719,
        "duration": 4.471
    },
    {
        "text": "that are interested in postdoc position",
        "start": 4163.359,
        "duration": 4.581
    },
    {
        "text": "I think we do have a project mapped out",
        "start": 4165.19,
        "duration": 5.159
    },
    {
        "text": "we're certainly not fixed to that if",
        "start": 4167.94,
        "duration": 5.169
    },
    {
        "text": "someone comes in with specific expertise",
        "start": 4170.349,
        "duration": 5.16
    },
    {
        "text": "in something else but this can give you",
        "start": 4173.109,
        "duration": 4.23
    },
    {
        "text": "some idea you know the types of projects",
        "start": 4175.509,
        "duration": 4.02
    },
    {
        "text": "we would like this candidate to work on",
        "start": 4177.339,
        "duration": 4.831
    },
    {
        "text": "and as Nick mentioned all of that would",
        "start": 4179.529,
        "duration": 4.17
    },
    {
        "text": "be publishable and it's really a",
        "start": 4182.17,
        "duration": 22.529
    },
    {
        "text": "requirement of the sounds good",
        "start": 4183.699,
        "duration": 24.781
    },
    {
        "text": "Thanks thanks for inviting us",
        "start": 4204.699,
        "duration": 8.611
    },
    {
        "text": "[Music]",
        "start": 4208.48,
        "duration": 4.83
    },
    {
        "text": "you",
        "start": 4213.7,
        "duration": 2.06
    }
]